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1.1  Zusammenfassung 
Pankreatitis ist eine entzündliche Erkrankung des Pankreas. Es wird durch verfrühte Aktivierung der 
Verdauungsenzyme in den Azinuszellen verursacht, was zu einer Selbstverdauung führt. Die milden 
Formen der Pankreatitis heilen normalerweise von selbst ab. Im Gegensatz dazu, sind die schweren 
Formen durch Nekrosen, Infektion, Organversagen und hohe Mortalität gekennzeichnet. Bei der 
chronischen Pankreatitis geht eine persistierende Entzündung mit Organschädigung einher. Dies führt 
zu intestinaler Maladsorption und endokrinem Funktionsverlust. Deshalb ist Pankreatitis immer noch 
eine klinische Herausforderung, assoziiert mit hoher Morbidität und Mortalität. Sowohl die akute wie 
auch die chronische Pankreatitis zeigen in vielen Ländern eine steigende Inzidenz. Es gibt keine 
kurativen Therapien, nur systemische Behandlungen mit unterstützender Wirkung. Es besteht also ein 
dringender Bedarf nach spezifischen Therapieansätzen, die aufgrund von Forschungserkenntnissen 
etabliert werden können.  
Epigenetische Modifikationen regulieren die Transkription der Gene, ohne eine Veränderung der 
zugrundeliegenden DNA-Sequenzen. Die Acetylierung ist eine der bekanntesten Modifikationen, die bei 
der Kontrolle der Transkriptionsaktivität von Histon-Proteinen ansetzt. Dabei spielen die 
Histonacetylasen (HAT) und Histon-Deacetylasen (HDAC) bei der Histon-Modifikation eine wesentliche 
Rolle, Histone werden acetyliert oder deacetylier. Die HATs spielen dabei eher die Rolle der Gen-
Aktivatoren während die HDACs die Gen-Inaktivierung fördern. Es ist jedoch so, dass HDAC auch 
einzelne Gene selektiv aktivieren können, was die Komplexität der Genregulation durch HDACs 
unterstreicht. In der Pathophysiologie vieler entzündlicher Erkrankungen scheint die Expression und 
Aktivität der HDACs eine bedeutende Rolle zu spielen, es ist jedoch nicht bekannt, ob HDACs auch bei 
der Pankreatitis wesentlich den Verlauf beeinflussen. In dieser Studie wurde deshalb untersucht, ob 
durch HDAC regulierte epigenetische Mechanismen in verschiedenen pankreatischen Krankheiten aktiv 
sind. Es wurden dazu Mausmodelle von akuter, chronischer und autoimmuner Pankreatitis verwendet. 
Wir konnten zeigen, dass während der entzündlichen Erkrankung die HDAC sowohl durch Transkription 
als auch Enzymaktivität hoch-reguliert wurden. Die grösste Veränderung wurde bei den Klasse I HDAC 
Enzymen beobachtet. Parallel dazu wurde eine Reduktion der Acetylierung von Kernproteinen 
festgestellt, was mit der Erhöhung der HDAC-Aktivität erklärbar ist. Um die Aktivität der Klasse I HDAC 
weiter zu charakterisieren, wurde ein selektiver Inhibitor (MS-275) verwendet, der sowohl in der 
experimentellen Pankreatitis, wie auch in Zellkultur an Makrophagen und Zell-Explantaten getestet 
wurde. Der Inhibitor hatte keinen Einfluss auf den primären Zellschaden, reduzierte jedoch die 
entzündliche Reaktion, sowohl der Makrophagen wie auch der T-Zellen während akuter und chronischer 
Phase. Zusätzlich untersuchten wir den Effekt der HDACs auf die regenerative Phase. Bei der 
Pankreasregeneration können Azinuszellen direkt proliferieren oder es findet eine Dedifferentiation der 
azinären Zellen statt (Azinus-zu-Dukt Metaplasie, ADM). Dieser Zustand gleicht einer Vorgängerzelle, 
die sich auch teilen kann. Diese Untersuchungen wurden wiederum am Tiermodell, sowie an 
Zellkulturen (AR42J-Zellen) mittels des spezifischen Klasse I HDAC Inhibitors MS-275 vorgenommen. 
Der Inhibitor induzierte die Transkription von Zyklinen und reduzierte damit die Proliferation der 
Azinuszellen. Zudem reduzierte MS-275 den DNA-Schaden und limitierte die Dedifferentiation in ADM, 
was sich auch auf die SOX9 Genexpression auswirkte. Schliesslich haben wir auch die Rolle der HDACs 
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in der Fibrose untersucht und konnten feststellen, dass die Inhibition mittels MS-275 zu einer Reduktion 
der Fibrose als Folge einer Interferenz des TGF-Signaltransduktionsweges führte. 
1.2 Signifikanz des Projektes 
Unsere Untersuchungen an Mausmodellen und in vitro Zellversuchen haben gezeigt, dass die 
epigenetische Regulation der Acetylierung durch die Klasse I HDACs eine wesentliche Rolle in der 
Pathophysiologie der akuten und chronischen Pankreatitis spielt. Vor allem zeichnet sich ein direkter 
Einfluss dieser Enzyme auf die entzündliche Reaktion, die Proliferation und Dedifferentierung der 
Azinuszellen, sowie des fibrotischen Prozesses ab. Zusammenfassend unterstützen unsere Daten ein 
mögliches Einsetzen von HDAC Inhibitoren als therapeutische Strategie zur Behandlung von 
Pankreatitis. Des Weiteren würde sich die beobachtete Hochregulation der Klasse I HDACs während 
der Autoimmun Pankreatitis als mögliches Ziel einer therapeutischen Intervention bei dieser Krankheit 
anbieten, insbesondere, weil die heutige Therapie mit vielen Rückfällen konfrontiert ist. 
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1.3 Summary  
Pancreatitis is a disease characterized by pancreatic inflammation. It is caused by premature intra-
pancreatic activation of digestive enzymes stored in acinar cells, leading to auto-digestion of the organ. 
Mild forms of acute pancreatitis are in general self-limiting. On the contrary, severe forms of the disease 
are associated with pancreatic necrosis, infection, organ failure and high mortality rates. Chronic 
pancreatitis is a long-term inflammation where the pancreas becomes permanently damaged, leading 
to intestinal malabsorption and endocrine dysfunction. Pancreatitis is still a clinical challenge associated 
with high risk of severe morbidity and mortality.  Both acute and chronic forms of pancreatitis have rising 
incidence in many countries. There is currently no cure for pancreatitis and the treatment is limited to 
supportive therapy. Thus, there is an urgent need for new therapeutic interventions. For this reason, 
further investigations are required to identify and develop new treatments for this debilitating disease.  
Epigenetic modifications regulate gene transcription without changing the DNA sequence. Acetylation 
is one of the most common epigenetic modification of histones and plays a major role in gene 
transcription control. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two 
families of enzymes that catalyze acetylation and deacetylation of histones, respectively. HATs are 
regarded as activators and HDACs as repressors of gene expression. Nevertheless, HDACs have also 
been linked to transcriptional activation of selected genes and deletion or inhibition of HDACs often 
results in the up-regulation or down-regulation of similar numbers of genes, indicating the complexity of 
HDAC-mediated control of gene transcription. HDACs expression and activity appear to contribute to 
the pathology of many inflammatory diseases. However, the role of HDACs during pancreatitis has not 
yet been investigated. Thus, in this study, we evaluated whether epigenetic mechanisms regulated by 
the activity of HDACs are involved in the development of cerulein-induced acute, chronic and 
autoimmune pancreatitis using different mouse models. We demonstrated that HDACs’ expression and 
activity were up-regulated in a time-dependent manner during the course of pancreatic inflammation, 
with the highest abundance observed for class I HDACs. Concomitant to this, decreased acetylation of 
nuclear proteins was observed. The functional relevance of class I HDACs was tested with the selective 
class I HDAC inhibitor MS-275, both in vivo upon cerulein induced-pancreatitis and in vitro in activated 
macrophages and primary acinar cell explants. MS-275 treatment did not prevent the initial acinar cell 
damage. However, it effectively reduced the infiltration of inflammatory cells, including macrophages 
and T cells, in both acute and chronic phases of the disease, and directly perturbed macrophage 
activation. In addition, we analyzed whether HDACs regulate the regenerative process of the pancreas 
following pancreatitis. Pancreatic regeneration involves proliferation of mature acinar cells and a 
transient de-differentiation of acinar cells to acinar-to-ductal metaplasia (ADM), a progenitor-like state, 
followed by cell division and re-differentiation. HDAC-dependent regulation of pancreatic regeneration 
was investigated in vivo and in vitro in the acinar cell line AR42J and in primary acinar cells with the 
specific class I HDAC inhibitor MS-275. Pharmacological inhibition of class I HDAC down-regulated the 
expression of late cyclins and reduced the proliferation of acinar cells. In addition, MS-275 treatment 
reduced DNA damage in acinar cells, down-regulated the progenitor-like gene Sox9 and limited acinar 
de-differentiation into ADM in a cell-autonomous manner by disrupting the EGFR signaling axis. Finally, 
SUMMARY  
  
 
 
 
8 
we analyzed the effect of MS-275 upon induction of chronic pancreatitis. We found that the inhibitor 
reduced the development of fibrosis by down-regulating TGF-signaling in the pancreas. 
1.4 Significance of the project.  
Our in vivo and in vitro investigations demonstrate that epigenetic regulation of acetylation mediated by 
class I HDACs plays a crucial role in the pathophysiology of acute and chronic phases of pancreatitis. 
Specifically, this study underlines the direct involvement of these enzymes in the development of 
inflammatory response, in the proliferation and de-differentiation of acinar cells into metaplastic lesions 
and in the fibrotic process in the damaged pancreas.  Collectively, our data support the potential of 
therapeutic strategies based on inhibition of class I HDACs during acute and chronic inflammatory 
insults of the pancreas. In addition, the upregulation of HDAC isoforms observed during autoimmune 
pancreatitis prompts the exploration of the therapeutic effect of HDAC inhibition in this type of chronic 
pancreatitis, the treatment of which remains challenging due to the high frequency of relapses. 
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2.1 Pancreas anatomy and physiology. 
The pancreas is an endocrine and exocrine gland of the gastrointestinal system. Anatomically, the 
pancreas is divided into three parts: the head that lies near the duodenum, the body, which includes the 
majority of the gland, and the tail that ends at the hilum of the spleen. Histologically, the endocrine and 
exocrine pancreatic tissue constitute 2% and 95% of the total pancreatic mass, respectively (Figure 1A).  
The endocrine tissue consists of different kinds of cells organized into islets of Langerhans distributed 
along the organ.  Each type of cell synthetizes specific hormones like insulin, glucagon, somatostatin, 
and pancreatic polypeptide and, following an appropriate stimulus, the hormones are secreted into the 
bloodstream to control blood sugar, energy metabolism, and storage throughout the body (Figure 1B).  
The exocrine tissue includes acinar cells organized in acini and ductal cells with associated connective 
tissue, vessels and nerves. The exocrine pancreas plays a central and essential role in the digestion of 
proteins, carbohydrates, and fat. (Figure 1B). 
2.1.1 The function of pancreatic acinar cells. 
Acinar cells are specialized to synthesize, store, and secrete different digestive enzymes. Although 
pancreatic amylase and lipase are secreted as active enzymes, generally the pancreatic digestive 
enzymes such as proteases and several other hydrolases are secreted as inactive zymogens [1]. 
Digestive enzymes and zymogens are secreted via the pancreatic duct into the duodenum where they 
are required for the digestion progression. There, these zymogens are converted into a mature and 
active enzymatic form by proteolysis, cleaving off a pro-peptide. Pancreatic secretion consists of an 
enzymatic component from acinar cells and an aqueous bicarbonate solution from the duct cells. 
Pancreatic secretory response is regulated by both neural and endocrine stimulation and their respective 
specific neurotransmitters and hormones receptors. Both kinds of receptors are present on the 
basolateral membrane of acinar cells. Furthermore, like the stomach, the pancreas is innervated by the 
vagus nerve that activates intra-pancreatic postganglionic neurons releasing acetylcholine (Ach), the 
primary secretagogue for acinar secretion, which initiates a modest secretory stimulus in response to 
ingestion of a meal. Acinar secretion is strongly stimulated upon food entry into the stomach by the 
hormones secretin and cholecystokinin (CCK), produced by intestinal endocrine cells upon detection of 
chyme. Both secretin and CCK stimulate acinar cells to produce and secrete their zymogen content, 
while inducing the gallbladder to contract and release bile into the duodenum [2]. In addition, secretin 
stimulates pancreatic and biliary ducts to secrete into the lumen bicarbonate, which neutralizes the 
acids, thereby balancing the pH and preventing acid-induced damage of the organs. (Figure 1C).   
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Figure 1. 
A 
B 
C 
Figure 1A. General anatomy of the pancreas. Figure 1B.  A pancreatic islet of Langerhans embedded in 
exocrine tissue. Figure 1C.  A single acinar cell. Black arrow indicated where zymogens are secreted.  
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2.2 Pathophysiology of pancreatitis. 
2.2.1 The inflamed exocrine pancreas: acute, chronic and autoimmune pancreatitis. 
Pancreatitis is an inflammation of the pancreas characterized clinically by abdominal pain, nausea and 
elevated levels of pancreatic enzymes, including amylase and lipase, in circulation. Acute pancreatitis 
is one of the most common diseases in gastroenterology. Repeated events of acute pancreatitis can 
lead to chronic pancreatitis. Both forms are serious and may result in severe complications. Progression 
from acute pancreatitis with mild symptoms to severe pancreatitis is a clinical challenge associated with 
high a morbidity and mortality rate. Although most of pancreatitis cases are mild and can be resolved 
within days or weeks, more severe cases are lethal due to multi-organ failure. The incidence of acute 
pancreatitis varies between populations from 4,9 to 35 per 100,000/year with considerable morbidity 
and mortality rates. Chronic pancreatitis also has a high mortality rate. However, it is variable depending 
on the cultural background. Nonetheless, acute and chronic pancreatitis consistently affect males twice 
as often as females. The etiology and pathogenesis of pancreatitis has been thoroughly investigated 
worldwide. Multiple factors can initiate or enhance injury of pancreatic cells, including heavy alcohol 
abuse, smoking, abdominal trauma, medications, infections, tumors, high triglyceride and calcium levels 
in the blood and anatomic abnormalities of the pancreas. About 80% of acute pancreatitis cases are 
due to the presence of gallstones in the gallbladder, which causes an obstruction of the normal flow of 
pancreatic fluid damaging  the acinar cells [3].  The production of inflammatory mediators from damaged 
acinar cells, as well as from the infiltrated inflammatory cells, leads to local and severe cases of systemic 
inflammation.  Systemic inflammation and multiple organ dysfunction syndrome (MODS), including lung, 
liver, kidneys and spleen, are the primary causes of morbidity and mortality in acute pancreatitis. 
The risk of chronic pancreatitis is greatest among users of alcohol and tobacco. Chronic pancreatitis is 
characterized by a progressive and irreversible inflammation of the pancreas, which triggers permanent 
damage of acinar cells due to the development of fibrosis. Consequently, there is an atrophy of acinar 
cells limiting the secretion of digestive enzymes. Ultimately, it leads to organ failure, intestinal 
malabsorption, weight loss and endocrine dysfunctions [4]. Besides inducing irreversible pancreatic 
damage, chronic pancreatitis increases the risk to develop pre-neoplastic lesions and pancreatic cancer 
[5, 6]. More recently, a new form of pancreatitis has been described, the so-called  autoimmune 
pancreatitis (AIP). AIP is a chronic inflammation caused by the body's immune system attacking the 
pancreas. This form of pancreatitis is rare and epidemiological data are available only relating to AIP in 
Japan, where national survey data estimates the prevalence of AIP as 0,82-2,2 per 100,000 individuals 
[7, 8]. This disease typically involves more men than women older than 50 years of age. Nowadays two 
subtypes of AIP are recognized, type 1 and type 2. Type 1 AIP is also called IgG4-related disease and 
affects multiple organs including the pancreas, bile ducts, salivary glands, kidneys and lymph nodes. 
Serologically, an elevated level of IgG4 is the most sensitive and specific finding in AIP type 1. 
Histologically, AIP type 1 is characterized by lymphoplasmacytic sclerosing pancreatitis (LPSP). LPSP 
is associated with: i) abundant levels of infiltrated lymphocytes, predominantly T cells, and plasma cells 
IgG4-positive. Neutrophils are rare in this type of pancreatitis. ii) Storiform fibrosis lesion, characterized 
by a deposition of disorientated collagen fibers forming a swirling pattern and, iii) by 
inflammation of veins that results in permanent closure of the vessel affected [9]. On the other hand, 
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AIP type 2 seems to be a pancreas-specific disorder. Even though about one-third of people with type 
2 AIP have associated inflammatory bowel disease, injury in other organs has not been reported in AIP 
type 2 [10, 11].  The main feature of this AIP type is the lack of abundant IgG4-positive staining plasma 
cells. Indeed, patients with type 2 AIP have no serological markers of autoimmunity. However, AIP type 
2 is characterized by diagnostic lesions termed granulocytic epithelial lesions (GEL), which are formed 
by an elevated number of neutrophils that ulcerate and destroy the ductal epithelium. GELs affect 
medium sized and small ducts, but also may be recognized in the acinar tissue. Contrary to AIP type I, 
this type of AIP present a moderate level of fibrosis centered on ducts [9]. Symptomatically, both types 
of AIP are indistinguishable. Many patients complain of abdominal pain, although the frequency and 
intensity of pain attacks seems to be lower in patients with type 1 AIP than type 2 AIP. Both subtypes of 
AIP are treated with corticosteroids, which in many patients dramatically improve the condition. 
However, relapses are common in AIP type 1 and rare in type 2.  
2.2.2 Development of inflammation. 
The early phases of acute pancreatitis are characterized by two major and independent cellular events: 
i) a premature intra-acinar activation of trypsinogen, leading to auto digestion and necrosis of the 
pancreas and ii) activation of NFκB signaling, leading to the development of inflammation [12]. 
Trypsinogen activation derives from abnormal fusion of lysosomal and zymogen granule compartments. 
Hence, it triggers the entire zymogen activation cascade with consequent acinar and tissue injury. 
Trypsinogen activation was believed to be the central pathogenic event of pancreatitis for many decades 
[13]. However, the inflammatory response triggered by NFκB signaling affects not only the pathogenesis 
but also the course of the disease [14], as it is the responsible for systemic effects and multi-organ 
failure.  Importantly, both trypsinogen and NFkB activation induce acinar cells to release an important 
number of inflammatory mediators, such as platelet activating factor (PAF), reactive oxygen species 
(ROS), transforming growth factor β (TGF-β), nitric oxide (NO), cytokines and chemokines.  Besides 
acinar cells, pancreatic stellate cells (PSCs) and resident macrophages also secrete these pro-
inflammatory mediators and play a dynamic role in recruiting leukocytes into the organ. They are 
essential determinants of local and systemic tissue injury. Amongst the leukocytes recruited, neutrophils 
aggravate the inflammation by releasing myeloperoxidase, reactive oxygen species (ROS) and 
proteolytic enzymes into the interstitium. In addition, monocytes and macrophages are also recruited to 
the pancreas, playing a critical role in the progression of the inflammatory response. They can change 
their physiology in response to the environment. During the initial stages of pancreatitis, infiltrated 
macrophages contribute to clearance of damaged cells via phagocytosis, but an impaired clearance of 
injured acini by macrophages is associated with an altered cytokine production, which stimulates a 
further immune response and recruitment of new leukocytes [15]. Macrophages can also induce tissue 
damage mainly via the production of reactive oxygen species. Thus, macrophages can promote the 
progression of inflammation. Indeed, the degree of macrophage activation is considered to be one of 
the main factors that determines the severity of acute pancreatitis [14, 16]. Several experimental and 
clinical reports indicate that the presence of pro-inflammatory stimuli induces classical activation of 
macrophages (M1 macrophages). During this activation, M1 macrophages are characterized by the 
secretion of pro-inflammatory cytokines, including TNFα, IL1β and IL6. In addition, they express 
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enzymes, such as inducible nitric oxide synthase (iNOS) or cyclooxygenase-2 (COX2), involved in the 
generation of other pro-inflammatory mediators as nitric oxide or arachidonic acid metabolites [17], 
which promote local and systemic inflammation. Although macrophages are the major leukocyte 
population found in the inflamed pancreas, other types of lymphocytes, including T lymphocytes and 
dendritic cells have also been described to play an important role in the development of acute 
pancreatitis [18, 19]. (Pancreatic inflammation is summarized in Figure 2A).    
2.2.3 Pancreatic regeneration. 
Organ regeneration is a common biological process involved in the natural turnover of cells.  In contrast 
to physiological regeneration, regeneration under pathophysiological conditions is always preceded by 
tissue damage. It results in disturbance of normal tissue architecture, loss of parenchymal cells and 
deposition of cellular debris. Following damage, it is necessary to restore normal organ structure and 
functionality. This is achieved by the integration, in time and space, of several complex biological 
processes. These complex mechanisms of regeneration consist of i) cell replication to compensate the 
loss of cells, ii) pattern formation to renew tissue architecture and ii) inflammation development to 
remove cellular debris. Rodent and human pancreas can regenerate from mild pancreatitis. Acinar cells 
have an important role in the regeneration of the exocrine pancreas. Rodent experimental models based 
on tamoxifen-inducible lineage-tracing, where the fate of acinar cells was compared before and after 
injury, demonstrated that most of the regenerated acinar cells derive from acinar cells already existing 
at the time of injury. Hence, these data demonstrated that acinar cell regeneration is driven mainly by 
proliferation of surviving acinar cells in cerulein-induced experimental pancreatitis or after partial 
pancreatectomy [20, 21]. However, the question remains whether a more severe injury may provoke an 
alternative form of regeneration. In this regard, new evidences of a different type of exocrine pancreas 
regeneration have been published (reference [12, 22]). In this work the authors used a model of 
regeneration based on severe pancreatic injury caused by diphtheria toxin. This approach induces an 
extensive ablation of acinar but not ductal cells. In this context, epithelial cells within the ductal 
compartment contributed to acinar cells regeneration. This regenerative mechanism recapitulated the 
embryonic pancreatic developmental program where the acinar cells are generated by ductal-to-acinar 
trans-differentiation rather than by acinar self-renewal. These results suggested that the capacity of 
epithelial ductal cells to adopt an acinar identity is context-dependent and that the severity of injury 
determines the regenerative mechanisms and cell types that contribute to this process. These results 
are very interesting, however further studies are required to understand their relevance in human 
pancreatic diseases. Another interesting aspect of pancreatic regeneration concerns the formation of 
acinar-to-ductal metaplasia (ADM), an acinar cell response to inflammatory injury. ADM is a 
reprogramming event that induces a morphological remodeling of the acinar architecture leading to a 
structural trans-differentiation of acinar cells into a ductal-like phenotype. This reprogramming consists 
of an initial downregulation of acinar-specific genes, followed by upregulation of ductal markers and 
pancreatic progenitor genes that recapitulates aspects of embryonic development [23]. The molecular 
factors that regulate ADM formation are complex. NFκB signaling pathway is a critical inducer of 
pancreatic inflammation and ADM [24]. In addition, both infiltrating inflammatory cells and acinar cell 
DNA damage are also associated with the development of ADM [20] [25]. Furthermore, EGFR signaling 
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plays a central role during ADM induction and progression in response to inflammatory signals [26] [27]. 
Usually, ADM formation is a reversible process during pancreatitis. In this context, several signaling 
pathways, including Notch [28], β-catenin [29], Sonic hedgehog (SHH) [30] and TGF [31], promote 
ADM re-differentiation into acinar cells in the injured organ and its return to normal phenotype.  However, 
several transgenic mouse models showed that persistent ADM is associated with impaired regeneration. 
Furthermore, in combination with genetic alterations, ADM can evolve into lesions known as pancreatic 
intraepithelial neoplasia (PanIN), which can further progress into pancreatic ductal adenocarcinoma 
(PDAC). Thus, the loss of acinar cell re-differentiation drives pancreatic cancer initiation, providing a 
mechanistic link between pancreatitis and cancer risk. Thus, it is still debated if ADM is required for 
organ regeneration or it is a side effect of pancreatic inflammation with potential negative implications 
for regeneration if not timely controlled. (Pancreatic regeneration is summarized in Figure 2B).   
2.2.4 Development of fibrosis.  
Development of fibrosis is a major histological feature of chronic pancreatitis. It is the result of a 
progressive necro-inflammatory condition causing irreversible damage to the pancreatic parenchyma. 
Excessive scarring constitutes the pathogenesis of pancreatic fibrosis. It is due to the production, 
deposition and contraction of extracellular matrix. In recent times, the identification, isolation and 
characterization of the cells that mediate the development of pancreatic fibrosis permitted significant 
progress in understanding this pathology.  These cells are called pancreatic stellate cells (PSCs). In the 
uninjured pancreas, PSCs are quiescent and can be identified by the presence of vitamin A-containing 
lipid droplets in the cytoplasm (see table 1) [32]. PSCs show a peri-acinar distribution and constitute 4% 
of all pancreatic cells [33].  In response to pancreatic injury or inflammation, quiescent PSCs become 
activated and transdifferentiate into myofibroblast-like cells, which express α-smooth muscle actin (-
SMA) (see table 1). Activated PSCs proliferate, migrate, produce extracellular matrix components, such 
as collagen, and express cytokines and chemokines [33, 34]. PSCs can be activated by a variety of 
toxic factors associated with pancreatitis, such as alcohol and its metabolites, endotoxin, oxidant stress, 
hyperglycaemia and hypoxia. In addition, soluble factors, including a variety of cytokines and growth 
factors, have been described to activate PSCs. In particular, platelet-derived growth factor (PDGF) is 
the major promoter of PSC migration, while transforming growth factor-β1 (TGF-β1) induces PSC to 
synthesize and secrete collagen, fibronectin and laminin via a Smad-associated pathway. [35]. Potential 
sources of these factors are activated macrophages, platelets, pancreatic acinar cells, ductal cells and 
endothelial cells in the inflamed pancreas.  In this context, it is known that acinar cells adjacent to fibrotic 
areas are strongly positive for TGB- suggesting that TGF- secreted by acinar cells could have a 
paracrine effect on PSCs, leading to an increased synthesis of collagen by PSCs [36, 37]. Importantly, 
PSCs by themselves are capable of synthesizing cytokines and chemokines, suggesting the existence 
of autocrine loops that might contribute to the perpetuation of PSC activation after stimulation by an 
initial exogenous signal, thus promoting the development of fibrosis [34]. (Development of pancreatic 
fibrosis is summarized in Figure 2C).   
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Table 1. 
Adapted from: Omary, Lugea et al. 2007 & Apte, Pirola et al. 2012 
 
Table 1. General characteristics of quiescent and activated pancreatic stellate cells (PSC).                                                          
- absence; + presence; ++ higlx present; +++ hugely present.  *PSCs molecular markers can diverge depend 
on cell activation state, organ and specie, i.e: 70%-80% of hepatic stellate cells (HSCs) on rat express desmin, 
whereas human HSCs seem to lack desmin expression.  
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A 
Figure 2. 
B 
C 
Figure 2A. Schematic representation of the pathophysiology of acute pancreatitis (AP). Figure 2B. Schematic 
representation of ADM formation during AP pancreatitis evolution. ADM lesions can re-differentiation into 
healthy acinar cells (regeneration) or toward to PaNIN lesions (impaired regeneration). Figure 2C. Schematic 
representation of fibrosis deposition during chronic pancreatitis (CP). Solid lines, direct effects.  
INTRODUCTIONRO 
  
 
 
 
 
18 
2.2.5 Pancreatitis: a therapeutic challenge 
There is currently no cure for pancreatitis and the goal of medical management is to provide supportive 
care. Initial analgesic therapy consists of pain-relieving and anti-inflammatory drugs to decrease 
pancreatic inflammation. Following the discovery of the central role of PSCs in pancreatic fibrosis, 
potential treatments have been proposed to target their activation. However, an effective anti-fibrotic 
therapy has yet to be established. To control malabsorption during chronic pancreatitis, pancreatic 
enzyme replacement therapy is recommended. Surgery intervention is indicated only in selected cases 
of acute and chronic pancreatitis to remove necrotic tissue, to correct organ abnormalities and to relieve 
pain. Thus, pancreatitis is still a clinical challenge and further investigations are urgently required to 
identify and develop new treatments for this debilitating disease. In this context, recent studies have 
shown that epigenetic mechanisms are activated in several organs during inflammatory and fibrotic 
diseases. Specifically, epigenetic modifications based on the activity of histone deacetylases (HDACs) 
and histone acetyltransferases (HAT) play essential roles in regulating transcription of genes critically 
involved in inflammation and fibrosis in kidney, liver, heart, and lung [38-43]. Thus, we investigated 
whether similar epigenetic mechanisms play a role in promoting the pathophysiology of acute and 
chronic pancreatitis and whether they may provide a novel therapeutic focus.  
2.3 Epigenetics  
The 20th century was the golden age of genetics. However, nowadays we know that gene expression 
does not just depend on the DNA sequence. It is also affected by epigenetic factors. The word 
“epigenetic” literally means “on top of genetic”. Thus, epigenetics is the study of heritable changes in 
gene expression that do not involve changes to the DNA sequence. Recently, histones have been 
shown to be dynamic proteins, which undergo multiple types of post-translational modifications to 
regulate chromatin condensation. This is an important process in the regulation of gene expression as, 
by altering the electrostatic forces of the chromatin and/or by altering the affinity of interactions with 
chromatin-binding proteins, histone modifications change DNA accessibility. Acetyl groups (acetylation), 
methyl groups (methylation), phosphor groups (phosphorylation), ubiquitins (ubiquitylation) and sumo 
groups (sumoylation) can modify histones. Besides histone modifications, other epigenetic mechanisms 
initiate and sustain epigenetic changes such as DNA methylation and non-coding RNA (ncRNA) [34].  
2.3.1 Histone modification: acetylation vs deacetylation.  
Acetylation of histone proteins was first discovered in the early 1960s and it is probably the best 
understood type of modification [44]. Acetylation occurs on lysine residues and it is a highly dynamic 
process regulated by the opposing action of two families of enzymes: histone acetyltransferases (HATs) 
and histone deacetylases (HDACs). HATs catalyze the transfer of an acetyl group from the acetyl 
coenzyme A metabolic intermediary to the ɛ-amino group of certain lysine residues in the basic N-
terminal tail region of histones [36]. This HAT action neutralizes the lysine’s positive charge and 
decreases the interaction of the N-terminal tail regions of histones with the negatively charged 
phosphate groups of DNA.  As a consequence, the structure of chromatin relaxes, thus facilitating 
access to the transcription machineries and promoting gene transcription. This chromatin relaxation is 
reversed by HDACs’ activity. HDACs remove acetyl groups from lysines, allowing interactions between 
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negatively charged DNA and positively charged histone proteins, which results in chromatin compaction 
and transcriptional silencing of genes. Hence, HDACs are predominantly transcriptional repressors 
enzymes. With their opposed regulatory activities, HATs and HDACs determine the level of histone 
acetylation in order to have a regulated gene transcription [37-40] (Figure 3, tables 2 and 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Since the discovery of HDACs the epigenetic ﬁeld has progressed rapidly. Several epigenetic studies 
have demonstrated that fundamental developmental signaling transduction pathways, that are quiescent 
in the adult organ, reemerge during organ injury as well as in tumorigenesis [23, 45]. During these 
processes, alterations of HDACs’ expression has been observed, concomitant with chromatin 
modiﬁcations and chromosome segregation defects, which could induce disease initiation and 
progression. The role of HDACs in the pathophysiology of several diseases opens up the possibility that 
epigenetic drugs may have a powerful impact on their treatment. Indeed, this possibility has been 
confirmed for cancer therapy. Food and Drug Administration has approved several HDAC inhibitors 
(HDACi) against specific types of cancer. These epigenetics drugs have been authorized based on their 
effectiveness in inhibiting tumor growth, their capacity to induce specific changes in gene expression 
Figure 3. 
Figure 3. Schematic representation histone acetyltransferase (HAT) and histone deacetylase (HDAC) 
enzymatic activity. Purple balls represents the histones. Blue balls (Ac) represents acetyl groups on the histone 
tails. Blue dash represents histone tails without Ac group. HAT and HDAC with opposed actions to maintain the 
steady-state levels of acetylation and control gene regulation. Acetylation (Ac) targets Lys residues in the 
amino-terminal tails of core histone proteins. Histone tail acetylated relaxes chromatin, and allows 
transcriptional activation. Histone deacetylate results in closed-chromatin configuration thereby blocking the 
access to transcription factors and other transcription co-activators inducing transcriptional repression.  
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and their influence on a variety of processes including differentiation, growth arrest, cytotoxicity and                                                                                                                                   
induction of apoptosis. Although HDACi were initially used as anti-cancer agents, they are now 
becoming a promising therapeutic approach for non-malignant diseases, including inflammatory 
diseases [39, 46]. Furthermore, recent data confirm that changes in the acetylation status of histones 
and abnormal expression and activation of antagonistic HATs and HDACs regulate inflammatory gene 
expression [47]. Indeed, in vitro and in vivo studies using HDACi have already shown positive 
therapeutic effects in a variety of animal models of inflammatory diseases, such as arthritis, inflammatory 
bowel diseases, ischemia-reperfusion injury, asthma, diabetes, acute kidney injury, spinal cord 
inflammation, demyelination, neuronal and axonal loss in experimental autoimmune encephalomyelitis 
[46, 48-50]. In addition to this anti-inflammatory effect, a growing body of evidence shows that epigenetic 
modulation through HDACi can have anti-fibrotic effects. Specifically, HDACi counteract the 
development of fibrosis in lung, liver, kidney and skin [39, 51-54]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 
Table 2. Histone Acetyltransferas (HAT) classification. There are two major classes of HATs described. HATs 
type-A and HATs type-B. The type-B are predominantly located in the cytoplasm acetylating free histones. The 
type-A HATs are a more diverse family than the type-B. The type-A HATs are classified into three separates 
groups depending on amino-acid sequence homology and conformational structure. Each of these enzymes 
modifies multiples sites within the histone N-terminal tails. 
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Table 3. Histone deacetylase (HDAC) classification. Isoforms of HDACs are divided into four classes based on 
the sequence similarity of their catalytic domain to yeast homologs. The distribution of the conserved catalytic 
domain and dominant region of subcellular localization are indicated. N; means Nucleos. C; means cytoplasm. 
M; means Mitochondria.  
 
Table 3. 
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3. Aim of the project.  
The functions of HDACs in the pancreas are still largely unexplored. A very interesting study revealed 
that HDAC activity is high in the embryonic pancreas and it plays a critical role in the development of 
the organ by orchestrating the gene expression that dictates the lineage of different cell types [55]. So 
far, the role of HDAC activity in the adult organ during diseased conditions, in particular pancreatitis, 
has not been thoroughly investigated. The few studies performed using different HDACi and different 
experimental models of pancreatitis presented conflicting results. Specifically, two recent studies 
showed that in vivo treatment with the pan-HDAC inhibitors sodium butyrate or trichostatin A (TSA), 
targeting both class I and class II subfamilies, alleviated pancreatic damage, inflammation and fibrosis 
following L-arginine [54] or taurocholic acid-induced pancreatitis [56] in rodents. However, another 
recent publication showed that treatment with the antiepileptic compound valproic acid (VPA), also 
known for its function as HDACi, increased pancreatic injury and it reduced the normal regenerative 
capacity of pancreatic acinar cells following cerulein-induced pancreatitis. [53].  Thus, further studies 
are needed to determine the function of HDACs during the development  and resolution of pancreatitis. 
To achieve this goal, we aim to: 
 Investigate whether HDAC activity is up-regulated during different phases of pancreatitis 
development. 
For this purpose, we evaluated the temporal regulation of HDACs in the different phases 
of the disease. First, we focussed on the early aspects that characterize the first week 
of pancreatitis (acute phase). Then, we evaluated the progression of the disease over 
six weeks of time (chronic phase). For these analyses, we induced pancreatitis by 
repetitive cerulein injections. Cerulein is a stable analogue of the hormone 
cholecystokinin (CCK), which, when administered at supra-maximal concentrations, 
induces aberrant pancreatic enzyme secretion, acinar cell damage and inflammatory 
phenotype typical of human pancreatitis. Finally, we investigated HDAC expression in 
the development of autoimmune pancreatitis. In this case, we used transgenic mice 
overexpressing lymphotoxin (LT)  and  in pancreatic acinar cells that spontaneously 
develop the disease at 12 months of age [57]. Using all these mouse models, we were 
able to characterize HDACs expression during the diverse phases and types of 
pancreatitis.  
 
 Assess the therapeutic value of class I HDAC inhibition during the development of 
pancreatitis.  
For this objective, we used the potent selective inhibitor of class I HDAC MS-275, also called 
Etinostat, a synthetic derivative of 2-aminophenyl benzamide. Nowadays there is growing 
interest for this specific epigenetic drug. Indeed, MS-275  is being tested in clinical phase 
III trials for receptor-positive advanced breast cancer and in phase II trials for lung cancer, 
breast cancer, and Hodgkin lymphoma [58]. In our case, the inhibitor was administered in 
both preventive and therapeutic regimens and its effects were evaluated during the acute 
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and chronic phases of the disease. Specifically, we focussed on the main features that 
characterize the progression of pancreatitis, namely initial damage of acinar cells, 
development of inflammation, acinar cell proliferation, formation of acinar-to-ductal 
metaplasia and organ fibrosis. 
To achieve the aims, i.e. the expression and activity of HDACs, the effects of class I HDAC inhibition 
with the selective inhibitor MS-275 during the different phases of pancreatitis and the identification of 
the underlying molecular mechanisms, we used in-vivo and in-vitro approaches, employing biochemical, 
qRT-PCR and imaging techniques.  
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ABSTRACT 
 
Background and Purpose  
Pancreatitis is a common inflammation of the pancreas with rising incidence in many countries. 
Despite improvements in diagnostic techniques, the disease is associated with high risk of 
severe morbidity and mortality and there is an urgent need for new therapeutic interventions. 
In this study we evaluated whether histone deacetylases (HDACs), key epigenetic regulators of 
gene transcription, are involved in the development of the disease.  
 
Experimental Approach  
We analyzed HDAC regulation during cerulein-induced acute, chronic and autoimmune 
pancreatitis using different transgenic mouse models. The functional relevance of class I 
HDACs was tested with the selective inhibitor MS-275 in vivo upon pancreatitis induction and 
in vitro in activated macrophages and primary acinar cell explants. 
 
Key Results  
HDAC expression and activity were up-regulated in a time-dependent manner following 
induction of pancreatitis, with the highest abundance observed for class I HDACs. Class I 
HDAC inhibition did not prevent the initial acinar cell damage. However, it effectively reduced 
the infiltration of inflammatory cells, including macrophages and T cells, in both acute and 
chronic phases of the disease, and directly perturbed macrophage activation. In addition, MS-
275 treatment reduced DNA damage in acinar cells and limited acinar de-differentiation into 
acinar-to-ductal metaplasia in a cell-autonomous manner by impeding the EGFR signaling axis.  
 
Conclusions and Implications These results demonstrate that class I HDACs are critically 
involved in the development of acute and chronic forms of pancreatitis and suggest that 
blockade of class I HDAC isoforms is a promising target to improve the outcome of the disease. 
 
Abbreviations 
 HDACs (histone deacetylases), ADM (acinar-to-ductal metaplasia), HDACi (HDAC 
inhibitor), TSA (Trichostatin A), GPT (glutamic-pyruvic transaminase), APCs (antigen 
presenting cells), H&E (hematoxylin and eosin), TUNEL (terminal deoxynucleotidyl 
transferase–mediated deoxyuridine triphosphate nick-end labeling, pH3 (Phospho-Histone 
H3), LT (lymphotoxin), CDKi (Cyclin-Dependent Kinase inhibitors) (CDKi), LPS 
(Lipopolysaccharide), i.p. (intraperitoneal). 
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INTRODUCTION 
 
Abnormal activity of histone deacetylases 
(HDACs), a family of enzymes involved in 
the epigenetic control of gene transcription, 
has been implicated in the etiology and 
development of several malignancies.  
However, recent evidence indicates that 
HDACs are also involved in the 
development of inflammatory diseases, 
highlighting the potential of targeting the 
activity of HDACs as a therapeutic approach 
to improve the outcome of rheumatoid 
arthritis [1, 2], neuritis [3, 4], cholitis [5] and 
autoimmunity [6]. 
HDACs control the acetylation status of 
histone and non-histone proteins, thus 
regulating the expression of target genes 
(reviewed in [7]). The complexity of 
acetylation-based epigenetic regulation is 
reflected by the size of the mammalian 
HDAC family, composed of eleven zinc-
dependent enzymes divided into three 
subfamilies (classes I, II, and IV) and seven 
NAD-dependent enzymes in a fourth 
(sirtuin) subfamily (class III), with non-
redundant functions. 
The function of HDAC subfamilies in the 
pathophysiology of pancreatitis, a highly 
debilitating inflammatory disease with 
potentially lethal outcome, has not been 
thoroughly investigated. During pancreatitis 
the organ is infiltrated by different leukocyte 
populations, with the most abundant being 
neutrophils, macrophages, T cells and 
dendritic cells. Differentiation and activation 
of these cell types are regulated by HDAC 
activity [8-10]. In addition, acinar cell 
proliferation and consequent organ 
regeneration is observed following 
inflammatory damage. This regenerative 
process is characterized by reactivation of a 
developmental-like program, the regulation 
of which is still elusive. Based on these 
observations, we hypothesize that HDAC 
activity may be a key factor in modulating 
not only leukocyte infiltration in the injured 
tissue but also gene expression changes in 
acinar cells affecting pancreatic 
regeneration. In support of this hypothesis, 
two recent studies showed that in vivo 
treatment with the pan-HDAC inhibitors 
sodium butyrate or trichostatin A (TCA), 
targeting both class I and class II HDAC 
subfamilies, alleviated pancreatic damage, 
inflammation and fibrosis following L-
arginine [11] or taurocholic acid-induced 
pancreatitis [12] in rodents. However, 
another study reported a detrimental effect 
upon treatment with valproic acid during 
cerulein-induced pancreatitis, with 
consequent delay in tissue recovery and 
reduced acinar cell proliferation [13]. These 
conflicting results highlight the need to 
further investigate the precise role of HDAC 
isoforms in this disease.  
In this study we dissected the temporal 
regulation of HDACs in different murine 
models of acute, chronic and autoimmune 
pancreatitis. Furthermore, we evaluated the 
therapeutic potential of class I HDAC 
inhibition to modulate pancreatic 
inflammation and tissue damage. 
 
METHODS 
 
Animal experiments  
All animal experiments were performed in 
accordance with Swiss Federal animal 
regulations and approved by the cantonal 
veterinary office of Zurich. All studies 
involving animals are reported in accordance 
with the ARRIVE guidelines for reporting 
experiments involving animals. Mice used in 
this study were adult 8–10 week old wild-
type C57BL/6 mice (Envigo Laboratories, 
Horst, The Netherlands), tryptophan 
hydoxylase-1 knocked-out mice 
(Tph1−/−)[14], mice with selective TGF-
receptor II ablation in pancreatic epithelial 
cells (Ptf1acre/+;Tgf-β RIIfl/fl)[15], 
lymphotoxin -overexpressing mice [16] 
and cyclin-dependent kinase inhibitor 
p21WAF1/Cip1 knocked-out mice (p21−/−) 
Jackson Laboratories, USA. Acute 
pancreatitis was induced via six 
intraperitoneal (i.p.) injections of 50 g/kg 
cerulein, administered hourly on two 
consecutive days. Control animals received 
0.9% NaCl injections. MS-275 
(Selleckchem, Houston, USA) was injected 
daily i.p. at 20mg/kg or 40mg/kg, starting 
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one day before the first cerulein injection. 
Control animals received vehicle DMSO 
injections.  Chronic pancreatitis was induced 
via six i.p. injections of 50 g/kg cerulein, 
administered hourly three times a week on 
alternate days (Monday, Wednesday, 
Friday) for up to six weeks. MS-275 was 
also administered three times a week on 
alternate days for two weeks starting 
concomitantly (preventive regimen) or one 
week after the beginning of cerulein 
injections (therapeutic regimen). Except for 
the mice harvested up to 8 hours after first 
cerulein-injection, animals did not receive 
cerulein or MS-275 on the harvest day. For 
autoimmune pancreatitis we used mice 
overexpressing lymphotoxin that 
develop the disease spontaneously at 12 
month of age [16]. 
Groups of 5 animals were tested for each 
experiment. Animals were assigned 
randomly to different experimental groups 
for all in vivo studies. Data collection and 
evaluation of all in vivo and in vitro 
experiments were performed blindly of the 
group identity. 
 
Mammalian cell cultures 
Acinar explants were obtained from 4-6 
week old wild-type C57BL/6 mice. Cultures 
of primary acinar explants were isolated 
according to [17] and embedded in collagen. 
De-differentiation into ADM was induced 
by addition of 50 ng/ml recombinant hTGFα 
(R&D Systems) for five days. Cultures were 
maintained in Waymouths MB 752/1 
medium supplemented with 50 U/mL 
penicillin, and 50 g/mL streptomycin, 0.1% 
fetal bovine serum (FBS), 0.1 mg/ml 
soybean trypsin inhibitor, and 1 μg/ml 
dexamethasone, with daily medium 
replacement. For RNA quantification 
following de-differentiation, explants grown 
in 12 well plates were isolated from the 
collagen matrix using 10 mg/mL collagenase 
(Sigma) for 15min at 37°C.  Samples from 
four replicas of each group were pooled for 
RNA extraction as described below. 
RAW264.7 macrophage cells were 
maintained in Dulbecco’s Modified Eagle 
medium (DMEM)+GlutaMAX 
supplemented with 10% fetal bovine serum 
(FBS), 50 U/mL penicillin, and 50 µg/mL 
streptomycin at 37°C in a 5% CO2 
atmosphere. Cells were pre-incubated with 1 
M MS-275 for 30 minutes and stimulated 
with 10 ng/mL LPS for six hours in the 
presence or absence of 1 M MS-275. 
Cell number, cell viability and cell diameter 
were determined using an automated cell 
counter (NucleoCounter® NC-200™, 
Chemometec, Allerod, Denmark).   
2*10E6 primary macrophages were isolated 
from the peritoneum of four mice, pooled, 
seeded in six well plates for two hours and 
stimulated as described above for RAW 
cells. At the end of the treatment, cells were 
lysed in the plate for RNA extraction. 
 
Immunohistochemistry  
Pancreas specimens were embedded in 
paraffin for histological analyses, as 
described[18]. Primary antibodies used in 
this study were: rabbit anti-Ki67 (#ab16667, 
Abcam, Cambridge, UK); rabbit anti-
phospho-histone 3 (#2066052, Millipore, 
MA, USA); rabbit anti-amylase (#A8273-
1VL, Sigma-Aldrich, Buchs, Switzerland); 
rabbit anti-PU.1 (#2266, Cell Signaling 
Technologies, Danvers, MA); rabbit anti-
acetyl-lysine (AcK) (#ab80178, Abcam); 
rabbit anti-phospho-histone H2A.X 
(Ser139) (#9718, Cell Signaling 
Technologies, Danvers, MA); rabbit anti-
coronin-1 (gift from Jean Pieters), Rabbit 
Anti-phospho-EGFR (Tyr1086) (Millipore); 
rabbit anti CD3 (#A 0452, Dako). Secondary 
antibodies used in this study were: Alexa 
Fluor 594 (A-11012, Thermo Fisher, 
Illkirch, France) and biotinylated goat anti-
rabbit IgG (H + L), included in the 
Vectastain® ABC Kit (PK-4001). Nuclei 
were visualized with 4,6-diamidino-2-
phenylindole (DAPI).  
Detection of DNA fragmentation in 
apoptotic cells was performed with a 
TUNEL assay using an ApopTag peroxidase 
Kit (MP Biomedicals, Illkirch, France).  
Microscopy analyses were performed on a 
wide-field Nikon Eclipse Ti (Amsterdam, 
The Netherlands). Quantification of labelled 
cells was performed in at least 10 randomly 
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selected high-power fields (×200) per slide 
using the NIS Elements BR Analysis and 
Cell^P analysis softwares.   
 
Western blotting 
Immunoblotting was performed by 
homogenizing tissue samples in RIPA buffer 
containing protease inhibitor cocktail 
(Roche Diagnostics, Mannheim, Germany). 
Protein concentrations were determined 
using a Bradford protein assay (BioRad, 
Hercules, CA, USA). 40 g protein aliquots 
were separated by SDS-PAGE 
electrophoresis and blotted using a V3 
Western Workflow system (BioRad, 
Hercules, CA, USA) according to 
manufacturer protocols. PVDF membranes 
were incubated with primary antibodies 
(rabbit anti-EGFR (# ab52894, Abcam); 
rabbit anti-α-Tubulin (#2125, Cell signaling) 
overnight at 4oC. All results were measured 
by densitometry and expressed by relative 
expression to tubulin as a reference protein. 
 
Nuclear protein extract and HDAC 
activity 
Nuclear proteins were extracted from 20 mg 
of pancreatic tissue with the EpiQuik™ 
Nuclear Extraction Kit (Epigentek Group 
Inc, Mountain View, CA) and HDAC 
activity was measured in the nuclear extracts 
with the fluorimetric EpiQuik HDAC 
Activity/Inhibition Assay Kit (Epigentek 
Group Inc. Mountain View, CA), following 
the manufacturer's instructions.  
 
Transcript analysis  
Total RNA was extracted from pancreatic 
tissue, acinar explants and cell lines, as 
described previously,[19] and reverse-
transcribed with qScript™ cDNA SuperMix 
(Quanta Biosciences). Gene expression was 
measured by real-time PCR on a 7500 Fast 
Real-Time PCR System (Applied 
Biosystems) using Taqman probes (Applied 
Biosystems). Transcript levels were 
normalized using 18S or HRPT RNA as a 
reference and expressed as Ct or Ct 
relative to the value of untreated control 
animals.  
 
Biochemical analyses of enzyme activity 
Levels of amylase and glutamate pyruvate 
transaminase (GPT) were measured in blood 
collected via heart puncture. Enzymes were 
measured using the Fuji Dri-Chem 4000i 
analyzer (FUJIFILM Corporation, Tokyo, 
Japan).  
Trypsinogen activation was measured in 
frozen pancreatic tissue as described 
previously [15]. 
 
Statistics  
Groups of 5 animals were tested for each 
experiment. The data are expressed as means 
± SEM. The statistical significance of 
differences in the means of experimental 
groups was determined using an unpaired, 
two-tailed Student's t test or one-way 
analysis of variance followed by Dunnett 
post test (GraphPad Prism 4.0c; GraphPad 
Software, Inc.) and a probability value <0.05 
was considered statistically significant. 
 
RESULTS 
 
HDAC activity is up-regulated in the 
pancreas during acute, chronic and 
autoimmune pancreatitis 
To test whether HDACs are regulated during 
acute pancreatitis, we induced the disease 
with serial cerulein injections according to 
the scheme depicted in Fig. 1A. Class I 
HDAC1-3 transcripts were the most 
abundant in the untreated adult pancreas 
(Fig. 1B), as previously reported [20], and 
the most up-regulated isoforms following 
pancreatitis. Increased HDAC expression 
was transient and returned to baseline levels 
over time for the majority of HDACs. 
HDAC activity also increased in the nuclei 
of pancreatic cells (Fig.1C), while nuclear 
acetylation decreased (Fig. 1D). Increased 
HDAC expression did not reflect the 
increased presence of leukocyte in the 
pancreas, as HDAC up-regulation i) 
preceded the peak of immune cell infiltration 
(Fig. S1A-C), ii) was detected also in 
isolated acinar cells 24h after induction of 
pancreatitis (Fig. S2A), and iii) was 
comparable in control and tryptophan 
hydoxylase-1 knock-out mice (Fig. S2B), or 
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TGF-receptor II knock-out mice (Fig. 
S2C), which we previously characterized 
with reduced [21] or increased [22] 
inflammation, respectively. Finally, HDAC 
up-regulation was restricted to pancreatic 
tissue, and unchanged in other organs, 
including spleen, lungs, liver and brain 24h 
after induction of pancreatitis (Fig. 1E). We 
then characterized HDAC expression during 
the course of chronic pancreatitis. Cerulein 
administration for up to six weeks, according 
to the scheme in Fig. 1F, resulted in 
progressive inflammation of the organ 
measured by up-regulation of inflammatory 
markers (Fig. S3A) and tissue damage (Fig. 
S3B). HDAC expression increased in a time 
dependent manner, reaching a plateau after 
four weeks of pancreatitis, with transcripts 
of class I HDACs being the most abundant 
(Fig. 1G). Increased HDAC expression was 
accompanied by increased enzyme activity 
(Fig. S3C). Finally, we investigated whether 
HDAC expression is regulated during the 
course of autoimmune pancreatitis (AIP). To 
this aim we used transgenic mice 
overexpressing lymphotoxin (LT) α and β in 
pancreatic acinar cells that spontaneously 
develop AIP at 12 months of age [16]. 
Besides developing autoantibodies, these 
animals are characterized by increased 
inflammatory infiltration, expression of pro-
inflammatory mediators (Fig. S3D) and 
formation of tertiary lymphoid organs 
(TLOs) in the pancreas (Fig. S3E). Similar 
to what we observed during cerulein-
induced pancreatitis, expression of HDAC, 
particularly of class I, was also up-regulated 
during AIP (Fig. 1H). Collectively, these 
data indicate that acute, chronic and 
autoimmune forms of pancreatitis trigger an 
increase of HDAC expression and activity in 
the pancreas.   
 
Inhibition of class I HDAC with MS-275 
reduces pancreatic inflammation 
following induction of acute and chronic 
pancreatitis.  
As members of class I HDACs showed the 
highest expression during the induction of 
pancreatitis, we first tested their functional 
relevance in the acute phase of the disease by 
administering the selective class I inhibitor 
MS-275 (Entinostat) according to the 
regimen in Fig. 2A. MS-275 treatment alone 
neither altered pancreatic tissue morphology 
(Fig. S4A) nor induced pancreatic (Fig. 
S4B) or liver damage (Fig. S4C). Following 
induction of pancreatitis, MS-275 abrogated 
pancreatic HDAC activity (Fig. 2B), without 
reducing the expression of HDAC 
transcripts (Fig. S5). Parameters of early cell 
damage, including levels of serum amylase 
(Fig. 2C), serum glutamic-pyruvic 
transaminase (GPT) (Fig. 2D), activation of 
acinar trypsinogen (Fig. 2E) and apoptosis of 
acinar cells (Fig. 2F) were not reduced in the 
presence of MS-275. Similarly, expression 
of CXCL2 and MCP-1, potent chemotactic 
proteins for neutrophils and 
macrophages/lymphocytes, were not 
reduced by MS-275 treatment (Fig. 2G). 
These data indicate that class I HDAC 
inhibition does not limit the initial cell 
damage triggered by cerulein-induced 
pancreatitis. Despite this phenotype, MS-
275 treatment decreased the infiltration of 
leukocytes in the pancreas (Fig. 2H, S6A), 
without reducing the expression of several 
pro-inflammatory molecules (Fig. S6B). 
Specifically, MS-275 decreased pancreatic 
levels of activated F4/80-positive 
macrophages (Fig. 2I), without affecting 
their polarization (Fig. 2J), and of CD3-
positive T cells (Fig. 2K, L), indicating that 
the inhibitor targets the infiltration of 
different leukocyte populations. 
The anti-inflammatory effect of MS-275 was 
also tested in the chronic setting of the 
disease after four weeks of cerulein 
injections (Fig. 1F), as this time point is 
characterized by sustained inflammation and 
extended tissue damage (Fig. S3). We 
compared a preventive regimen, where MS-
275 was administered for two weeks starting 
concomitantly with cerulein injections, and 
a therapeutic regimen more relevant for a 
clinical setting, where MS-275 treatment 
started a week after induction of pancreatitis 
(Fig. 3A). Both preventive and therapeutic 
regimens improved pancreatic morphology 
(Fig. 3B), significantly reduced pancreatic 
infiltration of leukocytes (Fig. 3C), 
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including macrophages (Fig. 3D, E) and 
CD3-positive T cells (Fig. 3E, F) and 
decreased the expression of pro-
inflammatory cytokines and adhesion 
molecules (Fig. 3E).  
 
Inhibition of class I HDAC with MS-275 
alters the activation of macrophages. 
As MS-275 treatment reduced macrophage 
infiltration during acute and chronic phases 
of pancreatitis, we then investigated whether 
MS-275 directly affects the activation of this 
cell type. Activation of RAW264.7 
macrophages with lipopolysaccharide (LPS) 
increased the expression of HDAC1 (Fig. 
4A) and HDAC activity (Fig. 4B). Pre-
incubation with 1 M MS-275 reduced the 
LPS-induced HDAC activity (Fig. 4B) 
without affecting cell viability (Fig. 4C). 
Moreover, MS-275 treatment altered 
RAW264.7 macrophage activation, as seen 
by limited LPS-induced size increase (Fig. 
4D), and deregulated the expression of 
selected inflammatory molecules, including 
decreased IL6 and increased IL1 levels 
(Fig. 4E). A similar deregulation of 
transcript expression was also observed in 
primary peritoneal macrophages stimulated 
with LPS in the presence of MS-275 (Fig. 
4F). 
 
MS-275 treatment results in reduced 
acinar replication following acute and 
chronic pancreatitis 
Following an inflammatory insult, acinar 
cells initiate a proliferation program to 
regenerate the damaged tissue. MS-275 
treatment decreased the number of 
replicating acinar (Fig 5A, B) and interstitial 
cells (Fig 5B, C). Expression of late cyclins 
A and B was also reduced (Fig. 5D), while 
early cyclin D and E expression was 
unchanged (Fig. S7A). Reduced replication 
was not paralleled by a general up-regulation 
of cyclin-dependent kinase inhibitors 
(CDKi). MS-275 treated pancreata showed a 
trend of increased expression only for the 
CDKi p21cip1/WAF (Fig. 5E), while the 
expression of other CDKis did not change or 
was reduced upon MS-275 treatment (Fig. 
S7B). To further investigate the role of p21 
in the observed MS-275 phenotype, we 
tested the effect of the inhibitor in p21 
deficient (p21-/-) mice upon induction of 
acute pancreatitis. Similar to what was 
observed in wild type mice, MS-275 reduced 
macrophage infiltration (Fig. 5F), acinar cell 
replication (Fig. 5G) and late cyclin 
expression, without up-regulating CDKi 
levels (Fig. 5H). These results suggest that 
the reduced cell replication upon MS-275 
treatment is not a consequence of increased 
CDKi expression. Finally, MS-275 
treatment during chronic pancreatitis also 
resulted in reduced replication of acinar and 
interstitial cells (Fig. 5I) and decreased 
expression preferentially of late cyclins (Fig. 
5J).   
 
Inhibition of class I HDAC ameliorates 
pancreatic tissue damage following acute 
and chronic pancreatitis  
The reduced number of replicating acinar 
cells upon MS-275 treatment may be a 
consequence of decreased acinar injury 
linked to the reduced inflammatory 
infiltration. In support of this hypothesis, 
DNA damage in acinar cells, known to be 
triggered by inflammation (reviewed in 
[23]), was lower in both MS-275-treated 
C57BL/6 and p21-/- mice, as shown by 
quantification of γH2AX (Fig. 6A), an early 
hallmark of active DNA damage response. 
Acinar DNA damage [24] and macrophage 
infiltration [25] are also associated with the 
development of acinar-to-ductal metaplasia 
(ADM), a transient de-differentiation of 
acinar cells occurring during the 
regenerative phase of pancreatitis. MS-275 
reduced ADM formation 72h after induction 
of pancreatitis (Fig. 6B). During ADM 
formation, acinar cells lose their mature 
phenotype, including amylase content, and 
express progenitor-like genes, such as Sox9. 
In untreated condition, Sox9 is detectable in 
the nuclei of centro-acinar and ductal cells; 
following an inflammatory insult, Sox9 is 
also transiently expressed by acinar cells, 
ductules and ADM (representative pictures 
of Sox9 staining are shown in Fig. 6C). 
Staining for Sox9 revealed that MS-275 
treatment reduced not only the amount of 
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ADM lesions but also the expression of Sox9 
in acinar cells (Fig. 6D). 
We further tested the effect of class I HDAC 
inhibition on tissue damage after four weeks 
of cerulein treatment. In the setting of 
chronic pancreatitis, parenchima 
degradation is more evident than in the acute 
phase of the disease, where ADM are present 
as focal lesions, and it is characterized by 
widespread areas with clusters of interstitial 
cells and ADM interspersed amongst intact 
acinar cells containing amylase. 
Quantification of damaged tissue showed 
that both preventive and therapeutic MS-275 
regimens effectively reduced the level of 
tissue damage (Fig. 6E) and the expression 
of progenitor-like genes (Fig. 6F). 
Moreover, we investigated whether factors 
promoting acinar de-differentiation into 
ADM were down-regulated by MS-275 
treatment. EGF-mediated signaling pathway 
is a potent inducer of ADM and malignant 
transformation [26]. We found that MS-275 
reduced the expression of EGF receptor 
(EGFR) in the pancreas at transcript (Fig. 
6G) and protein levels (Fig. 6H) and the 
amounts of its phosphorylated active form 
(Fig. 6I). 
 
Inhibition of class I HDAC reduces the 
formation of ADM in a cell autonomous 
manner 
Reduced EGFR expression upon MS-275 
treatment could derive from reduced 
production of EGFR ligands and receptor 
expression and activation or from a direct 
inhibition of EGFR expression in acinar 
cells by MS-275. To test the latter 
hypothesis, we triggered acinar cell explants 
de-differentiation into ADM by EGFR 
stimulation with TGF EGFR stimulation 
for five days was accompanied by up-
regulation of HDAC isoforms, with class I 
displaying the highest expression increase 
(Fig. 7A). MS-275 treatment reduced the 
formation of ADM in a dose-dependent 
manner (Fig. 7B) and prevented the up-
regulation of EGFR and ADM markers, such 
as cytokeratin 19 and Sox9 (Fig. 7C). 
Abrogation of ADM formation was not the 
result of acinar cell death, as acinar clusters 
that did not de-differentiate were 
metabolically active (Fig. 7D). These data 
indicate that class I HDAC inhibition 
prevents acinar de-differentiation into ADM 
in a cell autonomous manner and that the 
effect is likely mediated by a down-
regulation of the EGFR expression in acinar 
cells.   
 
DISCUSSION 
 
In this study we demonstrated that HDAC 
activity is up-regulated in the pancreas 
during acute, chronic and autoimmune 
pancreatitis in different mouse strains. 
Moreover, pharmacological inhibition of 
class I HDAC ameliorated the outcome of 
both acute and chronic forms of pancreatitis 
by reducing leukocyte infiltration and 
limiting tissue damage and acinar cell de-
differentiation into ADM. These results 
directly link the activity of class I HDACs 
with the pathophysiology of this severe 
disease. 
 
MS-275 and pancreatic inflammation 
The reduced inflammation observed 
following MS-275 treatment may result 
from different mechanisms. We found that, 
differently to what was observed upon pan-
HDAC inhibitor treatment [12], MS-275 
neither prevented the initial acinar damage 
nor the expression of chemokines necessary 
to recruit leukocytes. However, the inhibitor 
could directly affect leukocyte populations. 
Indeed, MS-275 altered the activation of 
macrophages and resulted in defective 
recruitment of these cells into the pancreas. 
Our results complement previous in vitro 
studies showing that MS-275 modifies the 
expression of inflammatory molecules and 
suppresses the migratory properties of 
antigen presenting cells (APCs), particularly 
macrophages and dendritic cells [10, 27]. As 
activated APCs regulate the activation of 
distinct inflammatory cell types, including T 
helper cells (Th1, Th2), T regulatory cells, 
neutrophils, monocytes, and B lymphocytes, 
it is clear that impairment of APC activation 
via HDAC inhibitors harbour the potential to 
inhibit immune processes at multiple levels. 
MANUSCRIPT A 
  
 
34 
Indeed, we also observed a reduced 
infiltration of CD3-positive T cells upon 
MS-275 treatment. 
Interestingly, the inhibitor down-regulated 
IL6, while up-regulated IL1in both 
RAW264.7 and primary macrophages. The 
biological significance of the different 
cytokine expression remains to be further 
elucidated, as they are able to exert both pro-
inflammatory and anti-inflammatory 
actions. Nevertheless, it is worth mentioning 
that IL1up-regulation was recently shown 
to induce apoptosis in bacterial-infected 
macrophages by inducing TNF [28]. Albeit 
we did not detect overt cell death of 
macrophages upon MS-275 treatment in the 
short term (hours) of our experimental 
setting, it is possible that long term (days) 
MS-275 incubation during pancreatitis may 
promote macrophage apoptosis and 
consequent reduced infiltration of these cells 
in the pancreas.  
 
MS-275 and ADM formation  
Our results revealed not only that acinar de-
differentiation into ADM was accompanied 
by increased HDAC expression but also that 
class I HDAC inhibition with MS-275 was 
sufficient to prevent ADM formation both in 
vitro and in vivo. In addition, our analyses 
highlighted the EGF receptor (EGFR) 
signaling pathways as the underlined 
molecular mechanism targeted by class I 
HDAC inhibition.  Specifically, we found 
that MS-275 treatment reduced the 
expression of EGFR in both in vivo and in 
vitro models, resulting in decreased acinar 
de-differentiation. These findings support 
the concept that increased class I HDAC 
activity in acinar cells is required to induce 
their de-differentiation into ADM by cell-
autonomous mechanisms. The described 
HDAC-mediated regulation of acinar de-
differentiation in the adult pancreas 
recapitulates what was previously identified 
during pancreatic development. In this 
context, global decrease in HDAC 
expression and activity, as well as increase 
in histone acetylation were observed in the 
organ during the transition from embryonic 
to adult stages. Not only cell differentiation 
into the various pancreatic cell types was 
concomitant with HDAC down-regulation, 
but also cell differentiation was modified by 
HDAC inhibition, therefore identifying the 
concerted and time dependent HDAC 
activity as a crucial regulatory factor for 
lineage commitment of the different 
pancreatic cell types [20, 29].  
Taking into consideration that i) HDAC 
activity supports acinar de-differentiation 
during development and in the adult state 
following inflammatory insult, ii) prolonged 
de-differentiation of acinar cells into ADMs 
is detrimental for pancreatic recovery 
following pancreatitis and iii) ADMs are 
considered pre-malignant lesions associated 
with the risk to develop pancreatic cancer, it 
is tempting to speculate that HDAC 
inhibitors harbour great potential as 
therapeutic agents in pancreatic 
inflammation. However, care has to be 
applied in the choice of the HDAC inhibitor, 
as treatment with valproic acid, an anti-
epileptic drug that also shows anti-HDAC 
activity, has been associated with 
development of pancreatitis in humans [30] 
and with disease exacerbation in mice, 
manifested by increased inflammation, 
decreased proliferation and persistent acinar 
de-differentiation with non-resolving ADMs 
[13].  
 
MS-275 and acinar cell proliferation 
Our results also revealed that MS-275 
treatment during pancreatitis was associated 
with a reduced number of proliferating 
acinar cells. This phenotype is likely to 
result from reduced tissue and DNA damage 
in acinar cells consequent to reduced 
inflammatory infiltration. However, 
dissecting the direct role of HDAC in acinar 
proliferation during pancreatitis is precluded 
by the interference of the inflammatory 
reaction, thus we cannot exclude that MS-
275 directly inhibits to some extent cell 
cycle progression in acinar cells. Increased 
HDAC activity is found in human pancreatic 
cancer cells [31, 32] and it is essential to 
support cell proliferation, NF-B activation 
and EMT transition [33, 34]. However, since 
the role of HDACs in pancreatic cancer cells 
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cannot be directly translated to non-
transformed acinar cells, additional non-
tumor based experimental models are 
required to address the role of HDACs in 
acinar cell proliferation. In this regard, we 
observed HDAC up-regulation following 
pancreas resection, an intervention that 
triggers acinar proliferation with minimal 
levels of tissue inflammation (data not 
shown). As HDACs support hepatocyte  
proliferation following liver resection [35], 
the role of HDAC in acinar cell proliferation 
following pancreatectomy warrants further 
investigation. 
 
Conclusions 
Our data directly link the expression of class 
I HDACs to the pathophysiology of acute 
and chronic pancreatitis and underline the 
direct involvement of these enzymes in the 
development of the inflammatory response 
and in the de-differentiation of acinar cells, 
as summarized in Fig. 7E.  Collectively, our 
data support the potential of therapeutic 
strategies based on inhibition of class I 
HDACs during pathological acute and 
chronic inflammatory insults of the 
pancreas. In addition, the up-regulation of 
HDAC isoforms observed during 
autoimmune pancreatitis prompts the 
exploration of the therapeutic effect of 
HDAC inhibition in this type of chronic 
pancreatitis, the treatment of which remains 
challenging due to the high frequency of 
relapses.   
While the safety of several HDAC 
inhibitors, including MS-275, as anti-cancer 
treatments has been ascertained [36], 
additional clinical trials are needed to 
determine the correct therapeutic regimen in 
the setting of pancreatitis. In addition, given 
the existence of many HDAC isoforms, 
further studies with genetic knocked out 
models are required to understand their 
specificity or redundancy of functions, based 
on which selective isoform-selective 
inhibitors can be exploited to minimize 
toxicity. 
 
All authors had access to the study data 
and had reviewed and approved the final 
manuscript. 
 
Acknowledgments  
We thank Jean Pieters, Biozentrum Basel for 
kindly providing the anti-coronin1 antibody. 
This research received grants from the Swiss 
National Science Foundation (Grant No. 
310030–146725) and the Amélie Waring 
Foundation. 
 
Author Contributions  
The authors of this manuscript contributed in 
the study design, acquisition, analysis, 
interpretation of data, drafting and critical 
revision of the manuscript. MB performed 
experiments, generated and analyzed data, 
wrote the manuscript; ES, EM, RC, GMS, 
AZ performed experiments, generated and 
analyzed data; TR generated transgenic 
lines; CH, EQ,RG revised the manuscript; 
SS designed the study, wrote the manuscript. 
All authors approved the submitted version. 
 
Conflict of interest 
The authors declare no conflicts of interest. 
 
Ethics approval  
Animal experiments were approved by the 
cantonal veterinary office of Zurich in 
accordance with Swiss Federal animal 
regulations.  
 
REFERENCES 
 
1. Choo, Q.Y., et al., Histone deacetylase 
inhibitors MS-275 and SAHA induced 
growth arrest and suppressed 
lipopolysaccharide-stimulated NF-
kappaB p65 nuclear accumulation in 
human rheumatoid arthritis synovial 
fibroblastic E11 cells. Rheumatology 
(Oxford), 2010. 49(8): p. 1447-60. 
2. Choo, Q.Y., et al., The histone 
deacetylase inhibitors MS-275 and 
SAHA suppress the p38 mitogen-
activated protein kinase signaling 
pathway and chemotaxis in rheumatoid 
arthritic synovial fibroblastic E11 cells. 
Molecules, 2013. 18(11): p. 14085-95. 
3. Zhang, Z.Y. and H.J. Schluesener, Oral 
administration of histone deacetylase 
inhibitor MS-275 ameliorates 
MANUSCRIPT A 
  
 
36 
neuroinflammation and cerebral 
amyloidosis and improves behavior in a 
mouse model. J Neuropathol Exp 
Neurol, 2013. 72(3): p. 178-85. 
4. Zhang, Z.Y., Z. Zhang, and H.J. 
Schluesener, MS-275, an histone 
deacetylase inhibitor, reduces the 
inflammatory reaction in rat 
experimental autoimmune neuritis. 
Neuroscience, 2010. 169(1): p. 370-7. 
5. Felice, C., et al., Review article: 
selective histone deacetylase isoforms 
as potential therapeutic targets in 
inflammatory bowel diseases. Aliment 
Pharmacol Ther, 2015. 41(1): p. 26-38. 
6. Hancock, W.W., et al., HDAC inhibitor 
therapy in autoimmunity and 
transplantation. Ann Rheum Dis, 2012. 
71 Suppl 2: p. i46-54. 
7. Delcuve, G.P., D.H. Khan, and J.R. 
Davie, Roles of histone deacetylases in 
epigenetic regulation: emerging 
paradigms from studies with inhibitors. 
Clin Epigenetics, 2012. 4(1): p. 5. 
8. Roger, T., et al., Histone deacetylase 
inhibitors impair innate immune 
responses to Toll-like receptor agonists 
and to infection. Blood, 2011. 117(4): p. 
1205-17. 
9. Bartels, M., et al., Histone deacetylase 
inhibition modulates cell fate decisions 
during myeloid differentiation. 
Haematologica, 2010. 95(7): p. 1052-
60. 
10. Nencioni, A., et al., Histone deacetylase 
inhibitors affect dendritic cell 
differentiation and immunogenicity. Clin 
Cancer Res, 2007. 13(13): p. 3933-41. 
11. Kanika, G., S. Khan, and G. Jena, 
Sodium Butyrate Ameliorates L-
Arginine-Induced Pancreatitis and 
Associated Fibrosis in Wistar Rat: Role 
of Inflammation and Nitrosative Stress. J 
Biochem Mol Toxicol, 2015. 29(8): p. 
349-59. 
12. Hartman, H., et al., Histone deacetylase 
regulates trypsin activation, 
inflammation, and tissue damage in 
acute pancreatitis in mice. Dig Dis Sci, 
2015. 60(5): p. 1284-9. 
13. Eisses, J.F., et al., Valproic Acid Limits 
Pancreatic Recovery after Pancreatitis 
by Inhibiting Histone Deacetylases and 
Preventing Acinar Redifferentiation 
Programs. Am J Pathol, 2015. 185(12): 
p. 3304-15. 
14. Walther, D.J., et al., Serotonylation of 
small GTPases is a signal transduction 
pathway that triggers platelet alpha-
granule release. Cell, 2003. 115(7): p. 
851-62. 
15. Grabliauskaite, K., et al., Inactivation of 
TGFbeta receptor II signalling in 
pancreatic epithelial cells promotes 
acinar cell proliferation, acinar-to-ductal 
metaplasia and fibrosis during 
pancreatitis. J Pathol, 2016. 238(3): p. 
434-45. 
16. Seleznik, G.M., et al., Lymphotoxin beta 
receptor signaling promotes 
development of autoimmune 
pancreatitis. Gastroenterology, 2012. 
143(5): p. 1361-74. 
17. Algul, H., et al., Overexpression of 
ErbB2 in the exocrine pancreas induces 
an inflammatory response but not 
increased proliferation. Int J Cancer, 
2007. 121(7): p. 1410-6. 
18. Silva, A., et al., COX-2 is not required for 
the development of murine chronic 
pancreatitis. Am J Physiol Gastrointest 
Liver Physiol, 2011. 300(6): p. G968-75. 
19. Graf, R., et al., Coordinate regulation of 
secretory stress proteins (PSP/reg, PAP 
I, PAP II, and PAP III) in the rat exocrine 
pancreas during experimental acute 
pancreatitis. J Surg Res, 2002. 105(2): 
p. 136-44. 
20. Haumaitre, C., O. Lenoir, and R. 
Scharfmann, Histone deacetylase 
inhibitors modify pancreatic cell fate 
determination and amplify endocrine 
progenitors. Mol Cell Biol, 2008. 28(20): 
p. 6373-83. 
21. Sonda, S., et al., Serotonin regulates 
amylase secretion and acinar cell 
damage during murine pancreatitis. Gut, 
2013. 62(6): p. 890-8. 
22. Grabliauskaite, K., et al., Inactivation of 
TGF-beta receptor II signaling in 
pancreatic epithelial cells promotes 
acinar cell proliferation, acinar-to-ductal 
metaplasia and fibrosis during 
pancreatitis. J Pathol, 2015. 
23. Kidane, D., et al., Interplay between 
DNA repair and inflammation, and the 
link to cancer. Crit Rev Biochem Mol 
Biol, 2014. 49(2): p. 116-39. 
24. Grabliauskaite, K., et al., p21(WAF1) 
(/Cip1) limits senescence and acinar-to-
ductal metaplasia formation during 
pancreatitis. J Pathol, 2015. 235(3): p. 
502-14. 
25. Liou, G.Y., et al., Macrophage-secreted 
cytokines drive pancreatic acinar-to-
ductal metaplasia through NF-kappaB 
and MMPs. J Cell Biol, 2013. 202(3): p. 
563-77. 
26. Means, A.L., et al., Pancreatic epithelial 
plasticity mediated by acinar cell 
transdifferentiation and generation of 
nestin-positive intermediates. 
MANUSCRIPT A 
  
 
37 
Development, 2005. 132(16): p. 3767-
76. 
27. Zhang, Z.Y. and H.J. Schluesener, 
HDAC inhibitor MS-275 attenuates the 
inflammatory reaction in rat 
experimental autoimmune prostatitis. 
Prostate, 2012. 72(1): p. 90-9. 
28. Jayaraman, P., et al., IL-1beta promotes 
antimicrobial immunity in macrophages 
by regulating TNFR signaling and 
caspase-3 activation. J Immunol, 2013. 
190(8): p. 4196-204. 
29. Haumaitre, C., O. Lenoir, and R. 
Scharfmann, Directing cell 
differentiation with small-molecule 
histone deacetylase inhibitors: the 
example of promoting pancreatic 
endocrine cells. Cell Cycle, 2009. 8(4): 
p. 536-44. 
30. Gerstner, T., et al., Valproic acid-
induced pancreatitis: 16 new cases and 
a review of the literature. J 
Gastroenterol, 2007. 42(1): p. 39-48. 
31. McCleary-Wheeler, A.L., et al., Insights 
into the epigenetic mechanisms 
controlling pancreatic carcinogenesis. 
Cancer Lett, 2013. 328(2): p. 212-21. 
32. Ouaissi, M., et al., Further 
characterization of HDAC and SIRT 
gene expression patterns in pancreatic 
cancer and their relation to disease 
outcome. PLoS One, 2014. 9(9): p. 
e108520. 
33. Aghdassi, A., et al., Recruitment of 
histone deacetylases HDAC1 and 
HDAC2 by the transcriptional repressor 
ZEB1 downregulates E-cadherin 
expression in pancreatic cancer. Gut, 
2012. 61(3): p. 439-48. 
34. Lehmann, A., et al., High class I HDAC 
activity and expression are associated 
with RelA/p65 activation in pancreatic 
cancer in vitro and in vivo. BMC Cancer, 
2009. 9: p. 395. 
35. Huang, J., E. Barr, and D.A. Rudnick, 
Characterization of the regulation and 
function of zinc-dependent histone 
deacetylases during rodent liver 
regeneration. Hepatology, 2013. 57(5): 
p. 1742-51. 
36. Ryan, Q.C., et al., Phase I and 
pharmacokinetic study of MS-275, a 
histone deacetylase inhibitor, in patients 
with advanced and refractory solid 
tumors or lymphoma. J Clin Oncol, 
2005. 23(17): p. 3912-22. 
 
MANUSCRIPT A  
  
 
 
 
 
38 
FIGURE LEGENDS 
 
Figure 1. HDACs are specifically up-regulated in the pancreas during acute and chronic 
pancreatitis. (A) Schematic representation of cerulein-induced acute pancreatitis. Grey boxes 
represent six intraperitoneal (i.p.) injections of 50 g/kg cerulein (Cer) administered hourly 
over two consecutive days. Black triangles indicate the time of animal harvest, counting from 
the first cerulein injection. (B) qPCR of HDAC isoforms in the pancreas at the indicated time 
of acute pancreatitis. (C) Total HDAC activity in pancreata at the indicated time after induction 
of pancreatitis. (D) Immunostaining of acetylated proteins in the pancreas using an anti-
acetylated lysine (AcK) antibody. (E) qPCR of HDAC isoforms in different organs 24h after 
induction of pancreatitis. (F) Schematic representation of cerulein-induced chronic pancreatitis. 
Grey boxes represent six cerulein injections administered on Monday, Wednesday and Friday. 
Animal harvests (black triangles) were performed on the following Monday after 2, 4 or 6 
weeks of treatment.  (G) qPCR of HDAC isoforms in the pancreas at the indicated time of 
chronic pancreatitis. (H) qPCR of HDAC isoforms in the pancreas of 12 month old wild type 
(WT) and lymphotoxin overexpressing (Tg+) mice with autoimmune pancreatitis. Results 
are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 2. MS-275 treatment does not limit the initial acinar cell damage but reduces the 
infiltration of inflammatory cells following acute pancreatitis. (A) Schematic representation of 
MS-275 regimen during induction of pancreatitis. Grey box represents the cerulein (Cer) 
treatment administered on two consecutive days. MS-275 was injected daily i.p. at 20 mg/kg 
(MS) or 40 mg/kg (2xMS). (B) HDAC activity in the pancreas following pancreatitis induction 
in the presence of MS-275. (C) Serum levels of amylase. (D) Serum levels of glutamic-pyruvic 
transaminase (GPT). (E) Quantification of pancreatic trypsinogen activation. (F)  
Quantification of TUNEL-positive apoptotic acinar cells. Right panel, representative image of 
stained cells (arrows). (G) qPCR of chemokine expression in the pancreas. (H) Quantification 
of PU.1-positive cells infiltrating the pancreas at the indicated time after induction of 
pancreatitis. Right panel, representative image of stained cells (arrows). (I) qPCR of the 
macrophage marker F4/80. (J) qPCR of macrophage subtype markers in pancreata. (K) qPCR 
of the T cell marker CD3 in pancreata.  (L) Quantification of CD3-positive T cells in pancreata. 
Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 3. Preventive and therapeutic administration of MS-275 reduces the infiltration of 
inflammatory cells following chronic pancreatitis. (A) Schematic representation of two weeks 
of preventive (MS+Cer, red box) and therapeutic (Cer+MS, orange box) MS-275 regimens 
during induction of chronic pancreatitis. Grey box represents the cerulein (Cer) treatment 
administered on alternate days over four weeks. MS-275 was injected i.p. on alternate days at 
20mg/kg. (B) Haematoxylin and eosin (H&E) staining of pancreata four weeks following 
induction of chronic pancreatitis in the presence of MS-275. (C) Quantification of PU.1-
positive cells infiltrating the pancreas. (D) Immunostaining of F4/80-positive macrophages 
infiltrating the pancreas. (E) qPCR of activated macrophages, macrophage subtypes, CD3-
positive T cells and pro-inflammatory markers in pancreata. (F) Immunostaining and 
quantification of CD3-positive T cells infiltrating the pancreas. Results are average ± SEM 
(n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 4. MS-275 treatment alters the activation of macrophages. (A) HDAC expression in 
RAW264.7 macrophages upon activation with 10 ng/mL LPS for 6h. (B) HDAC activity in 
LPS-treated RAW264.7 macrophages in the presence of 1 M MS-275. (C) Cell viability of 
LPS-treated RAW264.7 macrophages in the presence of 1 M MS-275. (D) Diameter increase 
of LPS-treated RAW264.7 macrophages in the presence of 1 M MS-275. Right panels, 
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representative micrographs of treated cells. (E) qPCR of inflammatory markers in LPS-
activated RAW264.7 macrophages incubated with 1 M MS-275. (F) qPCR of inflammatory 
markers in LPS-activated primary mouse macrophages incubated with 1 M MS-275. Results 
are average ± SEM (n=3), *P < 0.05. Scale bars: 20 m. 
 
Figure 5. MS-275 treatment reduces the number of proliferating cells in the pancreas during 
acute and chronic pancreatitis. (A) Quantification of Ki67-positive and pH3-positive acinar 
cells at the indicated time of pancreatitis induction. (B) Examples of Ki67 and pH3 
immunostainings. Acinar cells (arrows) were identified by large and round nuclei located inside 
the acinar periphery, while interstitial cells (arrowheads) had smaller and elongated nuclei 
present outside the pancreatic acini. (C) Quantification of Ki67-positive and pH3-positive 
interstitial cells. (D) qPCR of cyclin A and B expression in the pancreas. (E) qPCR of p21 
expression in the pancreas. (F) qPCR of inflammatory markers in p21 deficient (p21-/-) mice 
72h after induction of pancreatitis in the presence of MS-275. (G) Quantification of Ki67-
positive and pH3-positive acinar and interstitial cells in p21-/- mice 72h after induction of 
pancreatitis in the presence of MS-275. (H) qPCR of cyclins (Cy), CDK inhibitors and p53 in 
p21-/- mice 72h after induction of pancreatitis in the presence of MS-275. (I) Quantification of 
Ki67-positive acinar and interstitial cells after four weeks of chronic pancreatitis following 
preventive (MS+Cer) and therapeutic (Cer+MS) MS-275 regimens. (J) qPCR of cyclins after 
four weeks of chronic pancreatitis with preventive and therapeutic MS-275 regimens. Results 
are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 6. MS-275 treatment ameliorates the outcome of acute and chronic pancreatitis. (A) 
Quantification of H2AX-positive acinar cells, indicative of DNA damage, in wild-type 
C57BL/6 (BL/6) and p21 deficient (p21-/-) mice following acute pancreatitis in the presence of 
MS-275. Right panel, representative micrograph of stained acinar cells (arrows). I, islet. (B) 
Quantification of ADMs in BL/6 and p21-/- mice 72h after induction of pancreatitis in the 
presence of MS-275. Right panel, ADM areas (asterisks) are quantified after tissue 
immunostaining with amylase and are expressed as % of the total pancreatic area. (C) 
Immunostaining 48 hours after induction of pancreatitis showing Sox9-positive acinar (A) and 
centro-acinar (CA) cells, ductules (D) and ADM (asterisks). (D) Quantification of Sox9-
positive acinar cells during induction of pancreatitis in the presence of MS-275. (E) 
Quantification of non-acinar tissue after four weeks of chronic pancreatitis following preventive 
(MS+Cer) and therapeutic (Cer+MS) MS-275 regimens. (F) qPCR of progenitor-like markers 
after four weeks of chronic pancreatitis following preventive and therapeutic MS-275 regimens. 
(G) qPCR of EGF receptor (EGFR) after four weeks of chronic pancreatitis following 
preventive and therapeutic MS-275 regimens. (H) Western blotting quantification of EGFR 
expression after four weeks of chronic pancreatitis following preventive and therapeutic MS-
275 regimens. Band intensity values were normalized using tubulin as a loading control. (I) 
Immunostaining of phosphorylated EGFR (p-EGFR) showing the active form of the receptor 
after four weeks of chronic pancreatitis following preventive and therapeutic MS-275 regimens. 
Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m.  
 
Figure 7. MS-275 treatment reduces acinar de-differentiation into ADM. (A) qPCR of HDAC 
isoforms in acinar explants from BL/6 mice 5 days after TGF-induced de-differentiation. (B) 
Quantification of ADM in acinar explants after 5 days of TGF stimulation in the presence of 
MS-275 (MS) at the indicated concentrations. Right panels, examples of TGF-induced ADMs 
(arrows). (C) qPCR of EGF receptor (EGFR) and progenitor like-genes in acinar explants after 
5 days of TGF stimulation. (D) Metabolic activity of acinar explants visualized by reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into insoluble 
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chromogenic formazan blue crystals. (E) Schematic representation of the effects exerted by 
class I HDAC inhibition with MS-275 during acute and chronic pancreatitis. Solid lines, direct 
effects; dashed lines, potentially indirect effects. Results are average ± SEM (n=4), *P < 0.05. 
Scale bars: 50 m.  
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary figure 1. (A) Quantification of PU.1-positive cells infiltrating the pancreas at 
the indicated time after induction of acute pancreatitis. (B) Immunostaining of PU.1-positive 
cells in the pancreas. Right panel, example of positive cells (arrows). (C) Immunostaining of 
coronin-1-positive cells in the pancreas. Right panel, example of positive cells (arrows). Results 
are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
 
Supplementary figure 2. (A) qPCR of HDAC isoforms in isolated acinar cells isolated from 
pancreata 24h after induction of pancreatitis. (B) qPCR of HDAC isoforms in WT Tph1+/+ and 
Tph1-/- pancreata 24h after induction of pancreatitis. (C) qPCR of HDAC isoforms in WT and 
Tgf-RIIfl/fl pancreata 24h after induction of pancreatitis. Results are average ± SEM (n=5), *P 
< 0.05. 
 
Supplementary figure 3. (A) qPCR of inflammatory markers at the indicated time after 
induction of chronic pancreatitis.(B) Haematoxylin and eosin (H&E) staining of pancreata at 
the indicated time after induction of chronic pancreatitis. (C) HDAC activity in the pancreas 
following 4 weeks of chronic pancreatitis. (D) qPCR of inflammatory markers in 12 month old 
wild type (WT) and lymphotoxinoverexpressing mice (Tg+), which spontaneously 
develop autoimmune pancreatitis. (E) Haematoxylin and eosin (H&E) staining of pancreata 
from 12 month old WT and Tg+ mice. TLO, tertiary lymphoid organ, I, islet. Results are 
average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
 
Supplementary figure 4. (A) Haematoxylin and eosin (H&E) staining of pancreata at the 
indicated time upon treatment with 20 mg/kg MS-275 or vehicle control. (B) Quantification of 
serum amylase at the indicated time following MS-275 treatment. (C) Quantification of serum 
GPT at the indicated time following MS-275 treatment. Results are average ± SEM (n=5), *P 
< 0.05. Scale bars: 50 M. 
 
Supplementary figure 5. qPCR of HDAC isoforms in pancreata at the indicated time after 
induction of pancreatitis in the presence of MS-275. Results are average ± SEM (n=5), *P < 
0.05. 
 
Supplementary figure 6. (A) Coronin-1 staining of pancreata 48h after induction of 
pancreatitis in the presence of MS-275. (B) qPCR of inflammatory markers in pancreata at the 
indicated time after induction of pancreatitis in the presence of MS-275. Results are average ± 
SEM (n=5), *P < 0.05. Scale bars: 50 M. 
 
Supplementary figure 7. qPCR of cyclins (A) and cell cycle regulators (B) at the indicated 
time after induction of pancreatitis in the presence of MS-275. Results are average ± SEM 
(n=5), *P < 0.05. 
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ABSTRACT 
 
Pancreatic fibrosis is the hallmark of chronic 
pancreatitis, a highly debilitating disease for 
which there is currently no cure. The key 
event at the basis of pancreatic fibrosis is the 
deposition of extracellular matrix proteins 
by activated pancreatic stellate cells (PSC). 
Transforming growth factor  (TGF) is a 
potent pro-fibrotic factor in the pancreas as 
it promotes the activation of PSC. Thus 
pharmacologic interventions that effectively 
reduce TGF expression harbor 
considerable therapeutic potential in the 
treatment of chronic pancreatitis. In this 
study we investigated the molecular link 
between TGF expression and the activity of 
the epigenetic modifiers histone 
deacetylases (HDACs). To this aim, chronic 
pancreatitis was induced in C57BL/6 mice 
with serial injection of cerulein and the 
selective class I HDAC inhibitor MS-275 
was administered in vivo in a preventive and 
therapeutic manner. Both MS-275 regimens 
potently reduced deposition of extracellular 
matrix and development of fibrosis in the 
pancreas after four weeks of chronic 
pancreatitis. Reduced pancreatic fibrosis 
was concomitant to reduced PSC activation 
and lower expression of pancreatic TGF. In 
search of the cell types targeted by the 
inhibitor, we found that MS-275 treatment 
hampered the expression of TGFin 
isolated primary acinar cells. 
Our study demonstrates that MS-275 is an 
effective anti-fibrotic agent in the context of 
experimental chronic pancreatitis and thus 
may constitute a valid therapeutic 
intervention for this severe disease. In 
addition, it highlights the concept that TGF 
expressed by acinar cells may constitute a 
key factor in paracrine activation of PSC. 
 
INTRODUCTION 
 
Chronic pancreatitis is defined as a 
progressive inflammation of the pancreas. 
However, development of organ fibrosis is at 
the core of the disease pathophysiology. This 
progressive condition is characterized by 
irregular sclerosis with focal, segmental, or 
diffuse destruction of the parenchyma. As a 
consequence, gradual loss of exocrine and 
endocrine cellular components leads to 
pancreatic insufficiency and eventually 
diabetes, which are associated with 
considerable morbidity and reduction of the 
life quality and expectancy of patients 
(reviewed in (1,2)). 
Fibrosis is characterized by excessive 
production and deposition of extracellular 
matrix (ECM) components in the pancreatic 
parenchima. ECM proteins are mainly 
produced by pancreatic stellate cells (PSC) 
resident in the organ. In response to organ 
injury, released pro-fibrogenic factors 
activate PCS, a process characterized by 
phenotypical cell alteration, proliferation 
and ECM protein synthesis. 
Despite the research advances accomplished 
so far, the complex cellular and signaling 
mechanisms that drive the fibrotic process 
are not yet completely elucidated. This 
limited knowledge explains why therapeutic 
approaches that effectively counteract the 
development of organ fibrosis are not 
currently available and management of 
chronic pancreatitis remains a clinical 
challenge.  
In this study we evaluated whether 
administration of MS-275, a selective 
inhibitor of the epigenetic modifiers class I 
histone deacetylases (HDACs), counteracts 
the development of pancreatic fibrosis using 
the widespread murine model of cerulein-
induced chronic pancreatitis. The rationale 
for this approach is threefold i) epigenetic 
mechanisms are likely to orchestrate the 
substantial gene regulation observed in the 
development of fibrosis, ii) HDACs are 
critical epigenetic regulators and we found 
that expression of class I HDACs is 
significantly up-regulated during the course 
of chronic pancreatitis (Manuscript A), iii) 
pharmacological inhibitors of HDAC 
activity, while originally developed as anti-
cancer agents, are currently being 
investigated for their anti-fibrotic properties 
in different fibrotic diseases (recently 
reviewed in (3-6)).  
 
MATERIALS AND METHODS 
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Animal experiments 
All animal treatments were performed in 
accordance with Swiss Federal animal 
regulations and approved by the cantonal 
veterinary office of Zurich. 8 weeks wild-
type C57BL/6 mice (Envigo Laboratories, 
Horst, The Netherlands) were used. Animals 
were kept under standardized conditions 
under 12:12 light/dark cycles, with food and 
water available ad libitum.   
Chronic pancreatitis was induced via six 
intraperitoneal (i.p.) injections of cerulein 
(50g/kg) administered hourly every second 
day for up to 6 weeks. Control animals 
received 0.9% NaCl injections. MS-275 
(Selleckchem, Houston, USA) was injected 
i.p. at 20mg/kg every second day for two 
weeks starting concomitantly (preventive 
regimen) or one week after the beginning of 
cerulein injections (therapeutic regimen). 
Controls animals received DMSO injections. 
I.p. injections were alternated daily between 
left and right sides of the abdomen.  
 
Mammalian cell cultures 
Acinar cells were isolated from 6 week old 
Wistar rats from Charles River Deutschland 
(CRL).  Acini were pre-incubated with 1 M 
MS-275 for 30 minutes and stimulated with 
0.1 nM cerulein for 30 minutes in the 
presence of 1 M MS-275. At the end of the 
treatment, cells were lysed in the plates for 
RNA extraction and real-time PCR analysis. 
 
Immunohistochemistry  
Pancreas specimens were embedded in 
paraffin for histological analyses, as 
previously described (7). Hematoxylin and 
eosin and Masson's trichrome staining were 
performed according to routine procedures. 
α-SMA staining was performed with a 
mouse anti-α-SMA primary antibody (Dako, 
Glostrup, Denmark). Secondary antibodies 
used in this study were biotinylated goat 
anti-IgG (H + L), included in the 
Vectastain® ABC Kit (PK-4001).   
Microscopy analyses were performed on a 
wide-field Nikon Eclipse Ti (Amsterdam, 
The Netherlands). Quantification of labelled 
cells was performed in at least 10 randomly 
selected high-power fields (×200) per slide 
using the NIS Elements BR Analysis and 
Cell^P analysis software.   
 
Western blotting 
20 mg of pancreatic tissue was homogenized 
in RIPA buffer containing a protease 
inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany). Protein 
concentrations were determined by a 
Bradford protein assay (BioRad, Hercules, 
CA, USA). 20 g of proteins were resolved 
by SDS-PAGE electrophoresis and blotted 
onto nitrocellulose membranes using a V3 
Western Workflow system (BioRAd, 
Hercules, CA, USA) according to the 
manufacturer's protocols.  
Membranes were incubated with primary 
antibodies overnight at 4°C. Primary 
antibodies used in this study were: mouse 
anti-α-SMA (Dako, Glostrup, Denmark); 
rabbit anti -Tubulin (#ab52894, Abcam); 
rabbit anti-phospho-Smad3 (Ser423/425) 
(Cell Signaling, Danvers, MA, USA); rabbit 
anti-GAPDH (Santa Cruz Biotechnology, 
Dallas, TX, USA). 
 
Nuclear protein extract and HDAC 
activity 
Nuclear proteins were extracted from 20 mg 
of pancreatic tissue with the EpiQuik™ 
Nuclear Extraction Kit (Epigentek Group 
Inc, Mountain View, CA) and HDAC 
activity was measured in the nuclear extracts 
with the fluorimetric EpiQuik HDAC 
Activity/Inhibition Assay Kit (Epigentek 
Group Inc. Mountain View, CA), following 
the manufacturer's instructions.  
 
Transcript analyses  
Total RNA was extracted from pancreatic 
tissue and acinar explants as described 
previously (8) and reverse-transcribed with 
qScript™ cDNA SuperMix (Quanta 
Biosciences, Beverly, MA, USA). Gene 
expression was measured by real-time PCR 
on a 7500 Fast Real-Time PCR System 
(Applied Biosystems, Carlsbad, CA, USA) 
using Taqman probes (Applied Biosystems, 
Carlsbad, CA, USA). Transcript levels were 
normalized using 18S RNA as a reference 
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and expressed asCt relative to the value 
of control animals.  
 
Statistical analyses 
Groups of 5 animals were tested for each 
experiment. The data are expressed as means 
± SEM. The statistical significance of 
differences in the means of experimental 
groups was determined using an unpaired, 
two-tailed Student's t test or one-way 
analysis of variance followed by Dunnett’s 
post-hoc test (GraphPad Prism 4.0c; 
GraphPad Software, Inc.) and a probability 
value <0.05 was considered statistically 
significant. 
 
RESULTS 
 
Development of fibrotic response during 
chronic pancreatitis correlates with 
increased levels of HDAC expression. 
To investigate the role of HDAC in the 
development of pancreatic fibrosis 
following induction of chronic pancreatitis, 
we first performed a time-course analysis 
following induction of the disease to 
determine the kinetic of the fibrotic 
response. Histological evaluation of mice 
harvested after two, four and six weeks of 
cerulein treatment revealed a progressive 
damage of pancreatic parenchima and cell 
infiltration (Fig. 1A) and pronounced 
extracellular matrix (ECM) deposition (Fig. 
1B). Further quantification of fibrotic 
parameters showed that increased 
expression of collagen reached a plateau 
level after 4 weeks of pancreatitis (Fig. 1C). 
Development of pancreatic fibrosis is 
mediated by activated pancreatic stellate 
cells (PSCs), which constitute the 
predominant source of ECM proteins, 
including collagens and fibronectin. 
Activation of PSCs, detected by -smooth 
muscle actin (-SMA) expression, reached a 
plateau after 4 weeks of pancreatitis (Fig. 
1D), thus mirroring the kinetic of collagen 
expression. Expression of pro-fibrotic TGF 
isoforms, the main drivers of PSC activation, 
and TGF receptor also increased in a 
similar pattern (Fig. 1E), suggesting a 
concerted action of PCS activation and 
signalling mediators to promote the 
development of organ fibrosis. In addition, 
levels of pro-inflammatory factors followed 
a similar kinetic of expression in the 
pancreas (Fig. S1). Based on these results 
showing maximal levels of fibrosis after 4 
weeks of pancreatitis, we chose to focus on 
this time point for our further analyses.  We 
recently showed that gene expression levels 
of class I HDACs were upregulated during 
the course of chronic pancreatitis 
(Manuscript A). This was further confirmed 
by increased HDAC enzymatic activity (Fig. 
1F) in pancreatic nuclear proteins.  
 
Inhibition of class I HDAC with MS-275 
reduces the development of fibrosis 
following induction of chronic 
pancreatitis.  
To test whether class I HDAC up-regulation 
was functionally linked to the development 
of fibrosis, we treated mice with the selective 
class I inhibitor MS-275 (Entinostat). To this 
aim we administered the inhibitor for two 
weeks in a preventive manner, namely 
starting concomitantly with the first cerulein 
injection. Alternatively, we administered the 
inhibitor in a therapeutic manner, starting 
after one week of pancreatitis. Regimen 
schemes are depicted in Fig. 2A. Animals 
were harvested after four weeks of chronic 
pancreatitis. Histological examination 
revealed that both modalities of MS-275 
treatment resulted in better preservation of 
pancreatic parenchima and limited fibrosis 
(Fig. 2B). This was further confirmed by 
reduced collagen deposition (Fig. 2C) and 
reduced collagen expression following MS-
275 administration (Fig. 2D). As collagen 
deposition is mainly achieved by activated 
PSCs, we next evaluated whether PSC 
activation was reduced in the presence of 
MS-275. Gene expression of -SMA, a key 
hallmark of PSC activation, was lower upon 
MS-275 treatment (Fig. 3A). Reduced 
expression of -SMA was further confirmed 
at protein level by western blotting (Fig. 3B). 
These data revealed that both preventive and 
therapeutic regimens of MS-275 were 
effective in reducing PSC activation and 
consequently limiting the development of 
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fibrotic processes upon induction of chronic 
pancreatitis. 
 
Inhibition of class I HDAC with MS-275 
reduces TGF expression following 
induction of chronic pancreatitis.  
Activation of PSCs is initiated by damaged 
acinar cells and reinforced by already 
activated PSCs in a paracrine and autocrine 
manner through synthesis and secretion of 
pro-fibrotic mediators. Thus, we 
investigated whether the reduced fibrosis 
observed upon MS-275 treatment was linked 
to reduced expression of these factors. In 
support of this hypothesis, gene expression 
levels of pro-fibrotic TGF1-3 were lower in 
the presence of the inhibitor (Fig. 4A). 
Consequent to the deceased production of 
TGF isoforms, activation of TGF 
signaling was hampered, as shown by 
reduced phosphorylation of Smad3, an 
initiating event of the intracellular cascade 
resulting upon engagement and dimerization 
of TGF receptor complex (Fig. 4B). 
Interestingly, TGF receptor II was also up-
regulated following induction of 
pancreatitis, however its expression levels 
were not reduced following MS-275 
treatment (Fig. 4C), thus suggesting that the 
inhibitor decreased TGF signaling by 
reducing the expression of TGF isoforms 
rather than lowering the expression of their 
receptors.  
 
Inhibition of class I HDAC with MS-275 
reduces TGF expression in pancreatic 
acinar cells. 
Given the pivotal role played by TGF in the 
development of pancreatic fibrosis, we 
further evaluated the identity of TGF-
producing cells that are targeted by MS-275. 
Previous works showed that TGF is 
synthesized in activated PSC, thus acting 
through autocrine loops (reviewed in (9)). In 
our study, however, we investigated whether 
the synthesis of TGF upstream of PSC 
activation is inhibited by MS-275. 
Specifically, we asked whether damaged 
acinar cells following induction of 
pancreatitis up-regulate TGF expression in 
a HDAC-dependent manner. To exclude the 
confounding element of inflammatory and 
stromal components activated and recruited 
to the pancreas in vivo upon cerulein 
administration, we isolated primary 
pancreatic acini (Fig. 5A) and treated them 
in vitro with the drug. Cerulein treatment 
increased the expression of HDACs in 
isolated acini, especially evident for the 
HDAC1 isoform (Fig. 5B), suggesting that 
up-regulation of these enzymes is 
independent from the presence of stromal 
cells. Importantly, cerulein treatment also 
up-regulated the expression of TGF in 
acinar cells and pre-treatment with MS-275 
abrogated TGF induction (Fig. 5C), 
indicating that the inhibitor directly reduces 
TGF production in acinar cells. 
 
DISCUSSION 
 
A detailed understanding of the mechanisms 
driving the fibrotic process in the pancreas is 
still lacking and its achievement would 
constitute an essential component to design 
novel therapeutic intervention to cure this 
severe disease. TGF is a potent pro-fibrotic 
factor and plays a pivotal role in the 
development of fibrosis in chronic 
pancreatitis, as demonstrated by a 
conspicuous body of research in this field 
using a variety of genetic and 
pharmacological approaches to alter the 
levels of this molecule or inactivate its 
function (10-13). Importantly, these studies 
highlighted that fact that the TGF pathway 
is not only critical for the development of 
pancreatic fibrosis, but also has the potential 
to be targeted with beneficial therapeutic 
outcomes. 
One of the main effects exerted by TGF is 
activation of PSCs, which consists in a 
transformation from a quiescent state to a 
myofibroblast-like phenotype (reviewed in 
(9)). In recent years, activated PSCs have 
attracted increasing attention as major 
mediators of pancreatic fibrosis during 
chronic pancreatitis, as they not only 
mediate the development of fibrosis by 
producing ECM proteins, but also amplify 
the fibrotic response in an autocrine and 
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paracrine manner by secreting pro-fibrotic 
factors, including TGF(14). In the present 
study we discovered that expression and 
activity of HDACs in the pancreas is 
functionally linked with the development of 
organ fibrosis during chronic pancreatitis, 
thus providing a potential therapeutic target 
to counteract this disease. This hypothesis 
was further tested in in vivo experiments 
where the selective inhibitor of class I 
HDACs MS-275 was administered in a 
preventive or therapeutic manner during 
chronic pancreatitis. We observed a striking 
inhibition of pancreatic fibrosis and 
improved parenchima preservation in both 
regimen types, suggesting that MS-275 
exerts an anti-fibrotic effect even when 
administered after the commencement of the 
disease. 
At the cellular level, the reduced fibrosis 
detected upon MS-275 treatment was likely 
the result of reduced TGF expression, 
leading to a reduced conversion of PSCs 
from a quiescent to an activated state. An 
important question arising from these data is 
the identity of the cells whose TGF 
production is targeted by the inhibitor. Using 
in vitro experiments with isolated acinar 
cells we found that short term incubation 
with cerulein was sufficient to stimulate 
TGF expression in these cells. The fact that 
MS-275 treatment potently reduced 
cerulein-stimulated TGF expression 
suggests that acinar cells are indeed a direct 
target of the inhibitor and contribute to the 
phenotype observed in vivo.  
However, it is likely that acinar cells are not 
the unique source of TGF in the pancreas, 
as previous studies reported the presence of 
TGF1 mRNA in stromal cells upon 
induction of pancreatitis (15).  In this regard 
it is important to mention that TGF 
synthesis in non-acinar cells may also 
depend on HDAC activity. In fact, treatment 
of isolated PSCs with the pan-HDAC 
inhibitor sodium valproate was reported to 
inhibit TGF expression and collagen 
synthesis in these cells (16). Furthermore, 
another possible source of TGF production 
are inflammatory cells, which are recruited 
to the pancreas during the development of 
pancreatitis. This is of particular interest as 
we recently demonstrated that MS-275 
treatment effectively reduced the levels of 
inflammation during the course of acute and 
chronic pancreatitis (Manuscript A). Thus, 
while it is possible that reduced 
inflammation upon MS-275 administration 
leads to reduced fibrosis during chronic 
pancreatitis, a recent study revealed that 
development of inflammation and fibrosis 
are two independent and not causal events in 
this disease. Specifically, using transgenic 
mice deficient in Cxcr2, the authors 
observed almost complete ablation of 
inflammatory cell infiltration upon chronic 
pancreatitis. However, this limited 
inflammatory reaction did not prevent PSC 
activation and, consequently, fibrosis levels 
were comparable in transgenic and wild type 
control mice (17). This striking example 
implies that signaling molecules derived 
inflammatory cells, including TGF1, may 
play a minor role in the development of 
pancreatic fibrosis during chronic 
pancreatitis. 
Collectively, our results integrate with the 
current body of evidences demonstrating the 
critical role of HDACs in the development 
of fibrotic diseases. Examples in this regard 
are compelling evidences that HDAC 
activity is necessary for activation of hepatic 
stellate cells in vitro (recently reviewed in 
(4)). The requirement of HDAC activity in 
driving myofibroblastic differentiation and 
ECM protein synthesis was also observed in 
different fibroblast populations present in 
skin, lung, kidney (18-20). Moreover, the 
use of different HDAC inhibitors showed 
beneficial effects in the treatment of hepatic, 
renal, cardiac, pulmonary fibrosis in vivo 
(4,21-27). This suggests that epigenetic 
mechanisms controlled by HDACs may be a 
conserved feature in the development of 
different fibrotic diseases.  
 
Conclusion  
Counteracting the development of 
pancreatic fibrosis is a major and still 
unachieved therapeutic goal in the context of 
chronic pancreatitis. Our data revealed a 
potent anti-fibrotic effect of MS-275 
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treatment, which is mediated at least in part 
by suppression of TGF expression in acinar 
cells. This suggests on one hand that class I 
HDAC activity is critical for the timely 
controlled epigenetic regulation of key 
signaling molecules driving the 
development of fibrosis in this organ. On the 
other hand, this provides a new perspective 
on the cell type involved in regulating the 
process and highlights the possibility that 
acinar cells act as active mediators of 
pancreatic fibrosis. 
These results harbor important implications 
to further evaluate the therapeutic value MS-
275 in the context of chronic pancreatitis 
patients. Yet, future investigations using 
conditional knocked out mouse models are 
needed to achieve a global understanding of 
the individual HDAC isoforms’ function in 
the different cell types that are involved in 
the development of this disease. 
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FIGURE LEGENDS 
 
Figure 1. Characterization of chronic pancreatitis development. (A) Haematoxylin and eosin 
(H&E) and (B) Masson’s Trichrome staining of pancreata at the indicated weeks of pancreatitis 
induction revealed progressive destruction of parenchima morphology, cell infiltration and 
collagen deposition (green staining). (C) qPCR of collagen expression in the pancreas at the 
indicated weeks of pancreatitis. (D) qPCR of -smooth muscle (-Sma) expression in the 
pancreas at the indicated weeks of pancreatitis, indicative of pancreatic stellate cell activation. 
(E) qPCR of TGF isoforms and TGF receptor II (TGFRII) expression in the pancreas at the 
indicated weeks of pancreatitis. (F) HDAC activity in pancreata in the pancreas after four week 
of pancreatitis.  
Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 2. Preventive and therapeutic administration of MS-275 reduces the development of 
fibrosis during chronic pancreatitis. (A) Schematic representation of two weeks of preventive 
(MS+Cer) and therapeutic (Cer+MS) MS-275 regimens during induction of chronic 
pancreatitis. Cerulein (Cer) was administered on alternate days over four weeks. MS-275 was 
administered on alternate days over two weeks. (B) Masson’s Trichrome staining of pancreata 
showing reduced collagen deposition (green) after four weeks of chronic pancreatitis following 
preventive and therapeutic MS-275 regimens. (C) Densitometric quantification of collagen 
deposition visualized with Masson’s Trichrome staining. Results are expressed as % of the total 
pancreatic area. (D) qPCR of collagen expression. 
Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
 
Figure 3. Preventive and therapeutic administration of MS-275 reduces the activation of 
pancreatic stellate cells during chronic pancreatitis. (A) qPCR of -smooth muscle (-SMA) 
expression in pancreata after four weeks of chronic pancreatitis following preventive and 
therapeutic MS-275 regimens. (B) Western blotting quantification of -SMA in pancreata after 
four weeks of chronic pancreatitis following preventive and therapeutic MS-275 regimens. 
Band intensity values were normalized using tubulin as a loading control. 
Results are average ± SEM (n=5), *P < 0.05.  
 
Figure 4. Preventive and therapeutic administration of MS-275 reduces the expression of TGF 
during chronic pancreatitis. (A) qPCR of TGF isoforms expression after four weeks of chronic 
pancreatitis following preventive and therapeutic MS-275 regimens. (B) Western blotting 
quantification of phospho-SMAD3 in pancreata after four weeks of chronic pancreatitis 
following preventive and therapeutic MS-275 regimens. Band intensity values were normalized 
using Gapdh as a loading control. (C) qPCR of TGF receptor II (TGFbRII) expression in 
pancreata after four weeks of chronic pancreatitis following preventive and therapeutic MS-275 
regimens. 
Results are average ± SEM (n=5), *P < 0.05.  
 
Figure 5. MS-275 administration inhibits TGFb expression in acinar cells. (A) Micrograph of 
isolated pancreatic acinar cells. (B) qPCR of class I HDAC expression in isolated acinar cells 
upon in vitro treatment with cerulein. (C) qPCR of TGF1 expression in isolated acinar cells 
upon in vitro treatment with cerulein in the presence or absence of MS-275. 
Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 m. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary figure 1. qPCR of inflammatory markers in pancreata at the indicated weeks 
of pancreatitis induction. F4/80, marker of activated macrophages; IL6, interleukin 6; MCP-1, 
monocyte chemotactic protein 1. Results are average ± SEM (n=5), *P < 0.05. 
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6. Discussion  
A combination of epigenetic modifications generate a “histone code”. This histone code is vital to 
regulate gene expression independently of DNA sequence. Acetylation, methylation, phosphorylation 
and ubiquitination are the epigenetic modifications that occur on specific residues of histone tails and 
induce alterations in the helix of DNA affecting protein-protein interactions [59, 60]. The discovery of 
epigenetic modifications that affect gene expression has added another layer of complexity to the 
already tightly controlled regulatory machinery of the epigenome to control cell function, regulation, and 
identity. Histone acetylation is one of the best-studied epigenetic mechanisms. A dynamic balance 
between histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulates the status of 
histone acetylation. The balance between these enzymes is a key regulatory mechanism for gene 
expression and governs numerous developmental and disease state and cellular processes. Indeed, it 
has been demonstrated that elevated HDAC activity is required in embryonic development and 
organogenesis, while a dysregulation of HDACs has been linked to cancer, cardiovascular, immune and 
fibrotic disorders. Therefore, a big amount of basic research studies and human clinical trials are 
investigating the use of HDAC inhibitors as a treatment for a variety of disorders. Indeed, in this study 
we investigated the role of HDACs in the different phases that characterize the development of 
pancreatitis and the therapeutic value of HDAC inhibition. 
6.1 HDACs in early acinar cell injury and pancreatic inflammation development.   
Collectively, our data obtained from different models of pancreatitis provided the evidence that from the 
early onset to the chronic phase of pancreatitis, class I HDACs and nuclear HDAC activity were 
significantly increased. This was concomitant with a decrease in protein acetylation. Furthermore, HDAC 
up-regulation was restricted to pancreatic tissue, as HDAC expression did not change in other organs 
24h after induction of pancreatitis.  
Given the early HDACs up-regulation, specifically of class I HDAC, we investigated whether class I 
HDACs were promoting the onset of acinar cell damage. To assess the functional HDAC role during the 
initial phase of pancreatitis, we used MS-275, a selective inhibitor of class I HDAC. The initial acinar cell 
damage was measured by serum amylase, trypsinogen activation and acinar cell death. In any of our 
different mouse strains the parameters named above were not affected by class I HDAC inhibitor MS-
275, injected one day before cerulein-induced pancreatitis. Contrary to what was previously published.  
The pretreatment with the pan-HDAC inhibitor trichostatin A, which targets class I and class II HDACs, 
reduced the initial pancreatic damage evoked by taurocholate-induced acute pancreatitis [56]. Thus, 
differently from pan-HDAC inhibitor trichostatin A, the administration of MS-275 does not prevent the 
initial acinar cell damage. This data suggests that different HDAC classes, and possibly individual class 
members, may have different and non-redundant functions depending on the kind of initial damage. 
However, the two models represent different severities of pancreatitis and thereby, HDAC function may 
be different.  To resolve these apparently conflicting results, further studies using conditional KO mice 
for the different HDAC isoforms are needed to validate this concept.  Moreover, an initial acinar cell 
damage triggers the recruitment of leukocytes in the pancreas helping to develop an inflammatory 
response. The previous study using a pan-HDAC inhibitor showed reduced transcript levels for 
chemokines necessary to recruit leukocytes [56]. However, expression of the chemokines CXCL2 and 
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MCP-1 were not reduced in the presence of MS-275 in our model of cerulein-induced acute pancreatitis. 
Thus, these data are suggesting that the signals for leukocyte recruitment do not depend on class I 
HDACs. Despite the unchanged acinar cell damage and chemokine expression by MS-275 treatment, 
we provide evidence how MS-275 potently reduces the development of inflammation in the pancreas. 
This indicates that MS-275 reduced pancreatic inflammation independently from the initial acinar cell 
damage. A hypothesis explaining the observation that leukocytes are not responding properly to the 
injury is that MS-275 may have a direct inhibitory effect on leukocyte sub-populations. In support of this 
hypothesis, we have demonstrated that both, in the acute and chronic settings of pancreatitis, the 
recruitment of M1 and M2 types of macrophages and CD3-positive T cells were reduced in the presence 
of MS-275. Macrophages are one of the most relevant cell type in pancreatitis as they orchestrate both 
initiation and resolution of pancreatic inflammation. Furthermore, our in-vitro analyses with Raw264.7 
macrophages showed that activation of these cells with the pro-inflammatory stimulus 
lipopolysaccharide (LPS) resulted in increased expression of HDAC1 and increased nuclear HDAC 
activity. Importantly, incubation of Raw264.7 macrophages with MS-275 reduced their HDAC activity 
and altered their cytokine production. Together, these data suggest that MS-275 has a direct effect on 
macrophage activation. Interestingly, MS-275 treatment did not homogeneously repress cytokine 
expression in macrophages, but rather de-regulate their transcription in a selective manner. Specifically, 
IL-6 was strongly down-regulated, while IL1 was up-regulated in both, RAW264.7 and primary isolated 
macrophages upon LPS activation. The biological implications of differential cytokine expression 
following MS-275 treatment remains to be further elucidated, as they are able to exert both pro-
inflammatory and anti-inflammatory functions. An example in this regard is the finding that up-regulation 
of IL1 can induce apoptosis of bacterial-infected macrophages by inducing TNF [61]. Thus, up-
regulation of this cytokine observed in activated macrophages after MS-275 treatment suggested that 
they might promote macrophage apoptosis and consequently reduced infiltration of these cells in the 
pancreas during pancreatitis. Taken together, these results suggest that not only different leukocyte 
sub-populations are responsive to class I HDAC inhibition, but also that the molecular signals to develop 
pancreatic inflammation depends on class I HDAC activity. In fact, MS-275 treatment was previously 
shown to reduce the inflammatory response in animal models of rheumatoid arthritis [49], prostatitis 
[62], and neuritis [63]. Furthermore, treatment with other pan-HDAC inhibitors also ameliorated a wide 
spectrum of inflammatory diseases [64],  highlighting the potential of targeting HDAC enzymes as a 
therapeutic strategy. Moreover, with our results showing a robust decrease of leukocyte recruitment 
following MS-275 treatment during the course of acute and chronic pancreatitis,  the possible application 
of MS-275 as anti-inflammatory agents may be expanded to  pancreatitis. However, caution is warranted 
when using pan-HDAC inhibitors for clinical applications. A major issue with HDAC inhibitors is that 
HDAC isoforms may have different and non-redundant effects in the development of inflammatory 
diseases. In addition, many targets of HDAC inhibitors are currently not known Thus, there is much to 
learn about how HDAC inhibitors affect gene expression. However, it is clear that in the case of 
pancreatitis, the class I HDAC inhibitor MS-275 is predicted to be efficacious. Since the acetylated 
modification represents a novel anti-inflammatory strategy through regulating the expressions of 
inflammatory genes, characterization of the role of individual HDACs in driving inflammatory responses 
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may ultimately lead to the development of more selective HDAC inhibitors for specific anti-inflammatory 
applications depending on species, cell type, or the specific inflammatory mediators [65].  
6.2 HDACs in pancreatic regeneration  
The pancreas has a limited ability to recover and regenerate after injury. The pancreatic regenerative 
process is characterized by a transient de-differentiation of acinar cells to acinar-to-ductal metaplasia 
(ADM) [20, 25].  It is a complex reprogramming event observed during the regenerative phase of 
pancreatitis and is characterized by a cellular phenotype that expresses markers for pancreatic 
progenitor cells such as Sox9. Since aspects of embryonic development of the pancreas are re-
capitulated during recovery and regeneration following pancreatitis, it seems possible that the 
reactivation of progenitor genes during pancreatitis are regulated in a similar manner by HDAC activity 
following pancreatitis. Indeed, our results showed that acinar de-differentiation into ADM also was 
accompanied by increased HDAC expression. On the other hand, MS-275 treatment was sufficient to 
reduce HDAC expression and activity preventing ADM formation both, in vitro and in vivo. Previously, 
we described the correlation between inflammation levels and HDAC expression and it is know that 
macrophages can trigger ADM. Thus, ADM reduction seems to be an indirect effect derived from the 
reduction of macrophage infiltration after MS-275 treatment. However, we observed up-regulation of 
HDAC expression in the isolated acinar cells in the absence of inflammatory cells. This result 
corroborated the concept that class I HDACs activity was increased in acinar cells following induction of 
pancreatitis. Furthermore, it was necessary to induce acinar cell de-differentiation into ADM by cell-
autonomous mechanisms.  However, reduced ADM formation upon MS-275 treatment may result from 
other processes beside this specific epigenetic reaction. In fact, our results highlighted EGF receptor 
(EGFR) signaling pathway as underlying molecular mechanism targeted by class I HDAC inhibition. We 
observed a reduction of ADM by MS-275 concomitant with reduced expression of EGFR in both in-vivo 
and in-vitro systems reducing acinar de-differentiation. These findings support the essential function of 
HDACs for acinar de-differentiation during development and in the adult state following inflammatory 
insult.  It appears that EGFR signaling is part of the underliying molecular mechanism targeted by class 
I HDAC.  Importantly, the reactivation of developmental genes following pancreatitis culminates in an 
increased acinar cell proliferation. Class I HDACs have been found to play a central role in controlling 
cell cycle regulation including proliferation in non-cancerogenic mammalian systems [66]. Our mouse 
model showed reduced number of proliferating acinar cells after MS-275 treatment in acute and chronic 
pancreatitis.  This phenotype could result from a reduced DNA damage in acinar cells, reduced 
inflammation and reduced ADM. Nevertheless, we cannot exclude a direct effect of MS-275 on acinar 
cell cycle progression. Indeed, our results indicated that decreased replication of acinar cells observed 
following MS-275 treatment was due to a decreased expression of late cyclins.  In addition, more 
recently the same effect have been observed in other non-transformed cells, e.g. in the mouse liver after 
partial hepatectomy (PH). Following PH, the hepatic class I HDAC activity was significantly increased in 
nuclear and cytoplasmic fractions. Furthermore, these changes in hepatic class I HDAC expression, 
subcellular localization, and activity was concomitant with diminished histone acetylation during the 
regenerating liver phase [42]. Interestingly, when these mice were treated with suberoylanilide 
hydroxyamic acid (SAHA, a pan-HDAC inhibitor) an anti-regenerative effect was observed. SAHA 
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induced a delay on PH-induced histone deacetylation, damped hepatocellular proliferation, and blunted 
hepatic expression and activation of cell cycle signals downstream of cyclin D1 expression. Thus, this 
study demonstrates that HDAC activity promotes liver regeneration by regulating hepatocellular cell 
cycle progression downstream of cyclin D1 induction [42]. Overall, our data demonstrate that inhibition 
of class I HDAC with MS-275 ameliorates the outcome of acute pancreatitis. However, care has to be 
applied in the choice of the HDAC inhibitor. For example valproic acid treatment, an antiepileptic drug 
that also showed a pan-HDACs inhibitory activity, was associated with development of pancreatitis and 
multiorgan failure in humans [67-69]. In mice, it caused disease exacerbation, manifested by increased 
inflammation, decreased proliferation and persistent acinar de-differentiation with non-resolving ADMs 
[53]. At this point it is important to mention that prolonged de-differentiation of acinar cells into ADMs is 
unfavorable for pancreatic recovery following pancreatitis. Moreover, ADMs are considered 
premalignant lesions associated with the risk to develop pancreatic cancer. Therefore, further 
experiments are needed to assess the specific role of HDACs isoforms in non-transformed cells.  
6.3 HDACs in the development of pancreatic fibrosis   
The pathogenesis of chronic pancreatitis is characterized by development of pancreatic 
fibrosis.  Pancreatic fibrosis impairs exocrine and endocrine functions of the pancreas, leading to 
pancreatic dysfunction and severe impairment of patient’s quality of life.  In pancreatic fibrosis the 
equilibrium of extracellular matrix (ECM) formation and degradation is impaired, resulting in excessive 
deposition of ECM by an activated population of pancreatic stellate cells (PSCs). These activated PSCs 
transdifferentiate into myofibroblasts. They have characteristics that are intermediate between 
fibroblasts and smooth muscle cells, express alpha smooth muscle actin (α-SMA) and contractile 
proteins. In addition, they have higher rates of cellular proliferation and extracellular matrix deposition 
compared to fibroblasts. Therefore, they are considered the main producers of ECM, when become 
activated in the inflamed pancreas. ECM production in PSCs is regulated by fibrogenic growth factors. 
The main growth factors are transforming growth factor β1 (TGF-β1), platelet-derived growth factor 
(PDGF) and fibroblast growth factor (FGF), among other cytokines. These are produced by damaged 
acinar cells, inflammatory cells and activated PSCs. Thus, they can act in a paracrine and autocrine 
manner on PSCs. In particular, TGF-β is a key regulator of ECM formation and remodeling. It induces 
the expression of ECM proteins, proteases, and their inhibitors, such as the tissue inhibitors of 
metalloproteinases (TIMPs). Our in vivo data revealed that MS-275, in both preventive and therapeutic 
regimens, limited the activation of PSCs and reduced collagen deposition following induction of 
pancreatitis.  These data complement previous reports showing that HDAC inhibitors reduced the 
activation of PSCs and ECM deposition in vitro [70] and reduced the expression of pro-fibrogenic factors 
in these cells, suggesting that HDAC inhibitors may inhibit the autocrine activation of PSCs. Interestingly, 
we found that MS-275 directly inhibited TGF- expression in explanted acinar cells following cerulein-
induced damage.  Thus, the capacity of MS-275 to reduce the production of TGF in acinar cells, result 
in a diminished paracrine activation of PSC and consequent ECM deposition. These findings imply that 
MS-275 not only exerts a therapeutic effect in the early steps of the development of fibrosis upon 
induction of chronic pancreatitis, but also that it reduces pancreatic fibrosis by targeting both PSC and 
acinar cells. In addition to our findings, another study using a general pan-HDAC inhibitor, sodium 
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butyrate, demonstrated that HDACi are potent anti-fibrotic drugs in a different model of chronic 
pancreatitis. Specifically, the authors of this study showed that sodium butyrate treatment ameliorated 
the severe histological pancreatic changes observed during L-Arginine induced chronic pancreatitis in 
Wistar rats, [54].  Similar to our results using MS-275, sodium butyrate reduced collagen deposition and 
PSC activation, with consequent decrease of pancreatic fibrosis. Based on these similar results obtained 
with pan-HDAC and selective class I HDAC inhibitors it is likely that class I HDACs are the isoforms 
mainly responsible for the development of pancreatic fibrosis, however further studies are necessary to 
confirm this hypothesis.  
The anti-fibrotic effect of MS-275 is not restricted to the pancreas but has also been reported in the 
development of renal fibrosis [52]. In this study the authors observed less tubular dilatation, ECM 
deposition and fibroblast activation in the mouse model of unilateral ureteral obstruction (UUO) after 
MS-275 treatment compared to untreated kidney. Furthermore, the authors also demonstrated that the 
molecular mechanism behind reduced fibrosis following MS-275 treatment is the inhibition of TGB- 
expression[52]. Similar anti-fibrotic effects have been shown for pan-HDAC inhibitors in the case of skin 
and liver fibrosis [71-73].  
One important point that emerges from the available literature is that most of the studies focus on the 
effect of HDAC inhibitors, but the contribution of the individual HDAC isoforms during fibrosis is far from 
understood. Elucidating the role of HDAC isoforms would be highly relevant in clinical settings as: 1) 
different isoforms may have opposing roles in the development of fibrosis, 2) identifying the isoforms 
with pro-fibrotic roles would facilitate the development of specific inhibitors, which will likely result in 
more effective therapies than using pan-HDAC inhibitors. An example in this regard is the 
characterization of the functional role of different HDAC isoforms in cardiac fibrosis, which represents 
an adoptive response in the heart exposed to various stress (reviewed in [38]). These studies showed 
that class I and IIa HDACs have opposing functions in the regulation of fibrosis. Indeed, by use of 
HDAC2 knockout or transgenic mice investigating the function of cardiomyocytes, it turns out that 
HDAC2, a class I HDAC, induces cardiac hypertrophy in response to early hypertrophic stimuli whereas, 
class IIa HDACs including HDAC4, HDAC5, and HDAC9 suppress cardiac hypertrophy [38]. Thus, more 
research should be done using KO mice to reveal the specific mechanism by which individual HDACs 
participate in fibrosis.  
6.4 Conclusions  
The study reported here demonstrated that HDAC activity and expression were up-regulated in the 
pancreas during acute, chronic and autoimmune pancreatitis in different mouse models. In addition, we 
demonstrated the therapeutic value of the class I HDAC inhibitor Ms275, which can ameliorate the 
outcome of both acute and chronic forms of pancreatitis by reducing leukocyte recruitment, acinar-to-
ductal metaplasia and fibrosis. Furthermore, our data directly link the activity of class I HDACs with the 
pathophysiology of this severe disease. The involvement of these enzymes in the development of the 
inflammatory response, the de-differentiation of acinar cells and fibrosis production during acute and 
chornic pancreatitis, and their therapeutic value is summarized in Figure 4. Up-regulation of HDAC 
isoforms observed during autoimmune pancreatitis prompts the exploration of the effect of HDAC 
inhibition in this type of chronic pancreatitis for which the treatment remains challenging due to the high 
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frequency of relapses. While the safety of several HDAC inhibitors as anti-cancer treatments has been 
ascertained, including MS-275 [74], additional clinical trials are needed to determine the correct 
therapeutic regimen in the setting of pancreatitis. In addition, given the existence of many HDAC 
isoforms, further studies are required to understand their specificity or redundancy of functions, based 
on which isoform-selective inhibitors can be exploited to minimize toxicity. 
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